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behavior that accommodates the demands of a working muscle cell. Post-translationally detyrosinated
microtubules are physically coupled to the sarcomere, the contractile unit of the muscle, and resist both
the contraction and relaxation of the muscle. The cumulative impact of the microtubule network on
myocyte mechanics and the enzyme responsible for detyrosinating tubulin are unknown. Further, control
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stable, physically coupled microtubule network, yet the molecular determinates that govern dynamics
have not been studied in the cardiomyocyte. I hypothesize that depolymerization of the microtubule
network or knockdown of the vasohibin/small vasohibin binding protein complex, a putative tubulin
carboxypeptidase in cardiomyocytes, will improve the contractile kinetics of cardiomyocytes isolated
healthy or failing human hearts. Additionally, I hypothesize that desmin intermediate filaments may
stabilize growing microtubules at the sarcomere Z-disk in a detyrosination-dependent manner. Using a
combination of biochemical assays in tandem with direct observation of myocyte mechanics and
microtubule dynamics in primary adult cardiomyocytes I find the following: 1) depolymerization of the
microtubule network improves contraction and relaxation kinetics in cardiomyocytes isolated from failing
human hearts; 2) knockdown of either vasohibin 1 or small vasohibin binding protein reduced levels of
microtubule detyrosination resulting in improvements in contractile kinetics and a reduction in cellular
stiffness; and 3) tyrosination increases renders the microtubule more dynamic while desmin intermediate
filaments stabilize the growing microtubule. In summation, this dissertation establishes a mechanism for
the formation of the post-translationally detyrosinated microtubule network, and further underscores the
potential of detyrosination as a therapeutic target for the treatment of heart disease.
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ABSTRACT
MICROTUBULE POST-TRANSLATIONAL DETYROSINATION COORDINATES NETWORK
STABILITY AND MECHANICS IN THE CARDIOMYOCYTE
Alexander K. Salomon
Benjamin L. Prosser

The microtubule network of the cardiomyocyte exhibits specialized architecture,
stability, and mechanical behavior that accommodates the demands of a working
muscle cell. Post-translationally detyrosinated microtubules are physically
coupled to the sarcomere, the contractile unit of the muscle, and resist both the
contraction and relaxation of the muscle. The cumulative impact of the
microtubule network on myocyte mechanics and the enzyme responsible for
detyrosinating tubulin are unknown. Further, control of microtubule growth and
shrinkage dynamics represents a potential intermediate in the formation of the
stable, physically coupled microtubule network, yet the molecular determinates
that govern dynamics have not been studied in the cardiomyocyte. I hypothesize
that depolymerization of the microtubule network or knockdown of the
vasohibin/small vasohibin binding protein complex, a putative tubulin
carboxypeptidase in cardiomyocytes, will improve the contractile kinetics of
cardiomyocytes isolated healthy or failing human hearts. Additionally, I
hypothesize that desmin intermediate filaments may stabilize growing
microtubules at the sarcomere Z-disk in a detyrosination-dependent
manner. Using a combination of biochemical assays in tandem with direct
observation of myocyte mechanics and microtubule dynamics in primary adult
iv

cardiomyocytes I find the following: 1) depolymerization of the microtubule
network improves contraction and relaxation kinetics in cardiomyocytes isolated
from failing human hearts; 2) knockdown of either vasohibin 1 or small vasohibin
binding protein reduced levels of microtubule detyrosination resulting in
improvements in contractile kinetics and a reduction in cellular stiffness; and 3)
tyrosination increases renders the microtubule more dynamic while desmin
intermediate filaments stabilize the growing microtubule.
In summation, this dissertation establishes a mechanism for the formation of the
post-translationally detyrosinated microtubule network, and further underscores
the potential of detyrosination as a therapeutic target for the treatment of heart
disease.

v

TABLE OF CONTENTS

ACKNOWLEDGMENT ........................................................................................................... II
ABSTRACT ............................................................................................................................. III
LIST OF FIGURES ............................................................................................................... VII
CHAPTER 1: INTRODUCTION ........................................................................................... 1
Cardiomyocytes functionalize the heart ......................................................................................... 1
Cardiac microtubules resist myocyte motion ................................................................................ 2
Identification of the tubulin carboxypeptidase in cardiomyocytes ............................................ 6
Myocyte microtubule dynamics are influenced by tubulin tyrosination status and desmin intermediate
filaments ................................................................................................................................................ 8

CHAPTER 2: MICROTUBULES RESIST MYOCYTE CONTRACTION ............... 11
Depolymerization of the microtubule network in rat cardiomyocytes improves contractility
independent of the calcium transient ........................................................................................... 11
Depolymerization of the microtubule network improves contractility of failing human cardiomyocytes
............................................................................................................................................................. 13

CHAPTER 3: DEPLETION OF VASOHIBIN 1 SPEED CONTRACTION AND
RELAXATION IN FAILING HUMAN CARDIOMYOCYTES...................................... 16
Introduction ......................................................................................................................................... 16
Results.................................................................................................................................................. 19
Discussion............................................................................................................................................. 34
Methods ............................................................................................................................................... 37

CHAPTER 4: DESMIN INTERMEDIATE FILAMENTS AND TUBULIN
DETYROSINATION STABLIZE GROWING MICROTUBULES AT THE
CARDIOMYOCYTE Z-DISC ............................................................................................... 50
Introduction ......................................................................................................................................... 50
Results.................................................................................................................................................. 53
Discussion............................................................................................................................................. 73

vi

Methods ............................................................................................................................................... 75

CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS ...................................... 83
APPENDIX ............................................................................................................................... 91

vii

LIST OF FIGURES

Figure 1: Schematic depicting microtubule organization in the cardiomyocyte
Figure 2: Depolymerization of the microtubule network increases contractility of
isolated rat cardiomyocytes
Figure 3: Depolymerization of the microtubule networking improves contractility
of failing human cardiomyocytes
Figure 4: Identification of the primary cardiac detyrosinase and development of
tools to probe the tyrosination cycle
Table 1: Summary descriptive statistics of human hearts used in chapter 3
Figure 5: Validation of shRNAs specific for VASH1, VASH2 and SBVP
transcripts
Figure 6: TTL (tubulin tyrosine ligase) tubulin sequestration, but not
detyrosination, depolymerizes microtubules in healthy cardiomyocytes
Figure 7: Reducing detyrosination speeds contraction and relaxation of failing
human cardiomyocytes
Figure 8: SVBP knockdown improves contractility in both healthy and failing
isolated cardiomyocytes
Figure 9: VASH1 (vasohibin 1) knockdown reduces myocyte viscoelasticity and
improves contractility independent of changes to the calcium transient
Figure 10: Tyrosination specifically alters microtubule stability
Figure 11: Quantification of free and polymerized tubulin fractions presented in
figure 10
Figure 12: Tyrosinated microtubules are more dynamic
Figure 13: Supporting data for figure 12
Figure 14: Partial validation of MCAK knockdown
Figure 15: Desmin stabilizes the growing microtubule at the Z-disc
Figure 16: Supporting data for figure 15
Figure 17: Current working model for how the microtubule network is shaped by
tyrosination status and desmin intermediate filaments.
viii

CHAPTER 1: INTRODUCTION
Cardiomyocytes functionalize the heart

The capacity of the heart to pump blood at a rate sufficient to meet the
demands of the body is governed by the cardiomyocytes that make up the
myocardium, or muscular layer of the heart. The functional unit of the
cardiomyocyte is the sarcomere, which contains the actin and myosin that power
cardiomyocyte contraction. Upon calcium release from the sarcoplasmic
reticulum during systole, myosin interacts with actin to produce force leading to
myocyte shortening.1 The subsequent reuptake of calcium during diastole
dissociates actin and myosin leading to myocyte relaxation. The magnitude and
duration of calcium release thus controls the strength and speed of myocyte
contraction and relaxation.2
The left ventricle of the heart is the chamber responsible for circulating
oxygenated blood through the body. Inadequate relaxation of the ventricle due to
stiffening of the myocardium or diastolic dysfunction, alters the contractile
kinetics of the heart, potentiating a mismatch between the needs of the body and
cardiac output.3 Diastolic dysfunction is a hallmark of hypertrophic
cardiomyopathy and heart failure with preserved ejection fraction, complex
diseases characterized in part by stiffening of the ventricle leading to impaired
ventricular relaxation and slow ventricular filling.4 Impaired ventricular relaxation
1

is driven by both factors extrinsic to the cardiomyocyte, such as the composition
of the extracellular matrix, and intrinsic factors such as slowed or incomplete
reuptake of calcium which prevents complete deactivation of the sarcomere.5
Besides the contractile machinery, cardiomyocyte relaxation is influenced
by the presence of the non-sarcomeric cytoskeleton which includes microtubules,
intermediate filaments, and actin.

Cardiac microtubules resist myocyte motion

Figure 1. Schematic depicting microtubule organization in the cardiomyocyte

Microtubules are polymers of a and b tubulin that are critical in maintaining
cellular architecture6, signaling7,8, and proper RNA localization9 in the
cardiomyocyte. Individual a/b tubulin heterodimers self-assemble in a head-to-tail
fashion to form polarized protofilaments, of which 13 come together to form a
hollow tube with an outer diameter of ~25nm.10 Microtubules are characterized
2

by cyclical transitions between polymerization and depolymerization at their plusend, a behavior called dynamic instability.11–13 Both a and b tubulin isoforms bind
one guanosine triphosphate (GTP) molecule. While the GTP molecule bound to
a tubulin is not hydrolyzed nor exchanged, b tubulin hydrolyzes its GTP molecule
upon incorporation into the microtubule polymer. GTP hydrolysis to GDP by b
tubulin changes the conformation of the inter-dimer interface, which favors
depolymerization of the tubulin dimer.14,15 Thus, the presence of a GTP-cap on
the plus end of the microtubule stabilizes the growing tip16. Spatiotemporal
control of microtubule dynamics is cell type- and context-specific and can occur
either by controlling polymer addition or subtraction at the ends, or through lateral
interaction with the microtubule polymer.17
Control of microtubule dynamics and the resulting function of microtubule
sub-populations is maintained in part by post-translational modification of tubulin
or interaction with microtubule associated proteins. 17,18 Microtubules can be
post-translationally modified via the tubulin C-terminal tails that emanate from the
microtubule surface, as is the case of detyrosination19, glutamylation20, and
glycylation21. Post-translational acetylation22 and phosphorylation23 can also
occur within the globular region tubulin. By accruing post-translational
modifications, a microtubule code is thought to be ‘written’ that can be ‘read’ by
microtubule associated proteins.18 Microtubule associated proteins can either
provide structure to the microtubule, or utilize the microtubule as a substrate for
transport or depolymerization.24
3

Although microtubules are highly dynamic, they possess a relatively high
resistance to bending, or flexural rigidity, in relation to other cytoskeletal
elements.10,25 Upon compression, microtubules will bear compressive loads until
they reach a critical force that causes them to buckle. The critical buckling force
dictates how much resistance a microtubule provides to a compressive load.26–28
At relatively small compressive forces (1pN), a single in vitro microtubule will
form a single wavelength buckle. Through physical crosslinking with other
cytoskeletal elements in the cell and support from the crowded cytoplasm, the
compressive force microtubules can withstand can increase 1000x.29,30
The physical properties of the microtubule network are relevant to
myocyte contraction due to the organization of the network. In the cardiomyocyte
cytoplasm, hundreds of microtubules form a predominantly longitudinal network
that runs perpendicular to the transverse Z-discs that define the sarcomere.
Detyrosinated microtubules are physically coupled to the Z-disc via the
intermediate filament desmin that forms a honeycomb-like lattice around the
sarcomere.31 Upon contraction of the cardiomyocyte, these physically coupled
microtubules form short-wavelength buckles that provide resistance to
cardiomyocyte contraction.32 The interaction between the sarcomere and the
microtubule is dynamic and thought to function like a catch-bond, where the
strength of the bond increases with mechanical force.33 For example, at slow
rates of strain the microtubule will not engage with the sarcomere and produce
very little resistance to myocyte stretch, whereas at rapid length changes the
4

microtubule-sarcomere interaction will be engaged, producing what is known as
viscoelastic resistance.
The viscoelastic resistance provided by the microtubule network is
amplified during the progression of heart disease, where the microtubule network
proliferates and becomes largely detyrosinated. Experiments by George
Cooper’s group in animal models of heart disease established that the
cardiomyocyte microtubule network increases in density with cardiac hypertrophy
34

. Specifically, they found that pressure overload of the right ventricle in a feline

model of heart failure resulted in increased tubulin translation as well as
increased tubulin associated with the polymerized microtubule network.
Depolymerization of microtubules via the small molecule, colchicine, improved
the contractility of cardiomyocytes isolated from failing feline hearts. The resistive
effect of microtubules on the contractility of isolated wildtype cardiomyocytes
could be recapitulated by taxol treatment, a pharmacologic that promotes
microtubule stability. The role of microtubules in mediating pathologic changes to
contractility was further explored in vivo using a canine model of right ventricular
pressure overload 35. Colchicine treatment of dogs with heart failure resulted in
depolymerization of the microtubule network and restored ventricular contractility,
suggesting that microtubules resist cardiomyocyte contractility.
While Cooper’s data suggest that microtubules resist cardiomyocyte
contraction, other groups found that microtubule depolymerization has a
negligible impact on improving ventricular contractility in a guinea pig model of
heart failure36 and in a feline model of cardiac hypertrophy37. In chapter 2, I
5

interrogate the role of microtubules in cardiomyocyte contractile dynamics in
wildtype rat cardiomyocytes and in cardiomyocytes isolated from non-failing and
failing human hearts. In collaboration with Matthew Caporizzo and Christina
Chen, the lead authors of the articles in which my work was published, we
hypothesize that the microtubule network resists myocyte contractility. I find that
depolymerization of the microtubule network with colchicine, a small molecule
that depolymerizes microtubules, improves the contractility of isolated rat
cardiomyocytes and cardiomyocytes from failing human hearts independent of
changes to the calcium transient.
Identification of the tubulin carboxypeptidase in cardiomyocytes
Detyrosination was one of the first identified post-translational
modifications of tubulin19 and is commonly associated with a stable microtubule
population that has a comparatively longer half-life than tyrosinated
microtubules38. Detyrosination on its own is not sufficient to change the inherent
stability of the microtubule.39,40 The observed increase in relative stability of
detyrosinated microtubules is due to altered interaction with microtubule
associated proteins41. For example, tyrosination selectively increases the
localization of CLIP-170, a protein found at the plus-end tip of the microtubule
that increases microtubule catastrophe rate. 41
Initially, the contribution of detyrosinated microtubules to myocyte
mechanics was interrogated by treatment with parthenolide, a sesquiterpene
lactone thought to inactivate the tubulin carboxypeptidase. While treatment of
6

isolated cardiomyocytes with parthenolide reduces detyrosination and
subsequently increases contractility, parthenolide treatment also alters the
calcium transient.42 Further, parthenolide has been shown to covalently bind to
tubulin which prevents tubulin incorporation into microtubules.43 Detyrosination
can more specifically be decreased by overexpression of tubulin tyrosine ligase
(TTL), the enzyme responsible for ligating the terminal tyrosine residue back to
detyrosinated tubulin.44,45 Overexpression of TTL in cardiomyocytes from patients
with heart failure reduces cardiomyocyte stiffness and improves contractility.32,46
However, the precise mechanism by which TTL modulates myocyte mechanics is
unclear, as in addition to its tyrosination activity, TTL can depolymerize
microtubules by binding free tubulin dimers, preventing their incorporation into
polymerized microtubules.44 Because it is mechanistically unclear if TTL exerts
its effects via changes in microtubule detyrosination, depolymerization, or both,
methods to more specifically alter detyrosination are necessary to fully
understand the mechanism of TTL action and to better define therapeutic targets
for heart failure.
The identity of the carboxypeptidase responsible for tubulin detyrosination
was unknown until recently, when two groups independently identified the
complex of vasohibin-1/2 (VASH-1/2) and small vasohibin binding protein (SVBP)
as the primary detyrosinating enzyme in neurons47,48. It is currently unknown if
the VASH-SVBP complex functions as a detyrosinating enzyme in
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cardiomyocytes and may represent an important therapeutic target in the
treatment of heart disease.
In chapter 3 I provide evidence that the VASH-SVBP complex functions as
a primary detyrosinating enzyme in cardiomyocytes. I find that knockdown of
either VASH or SVBP results in a reduction of detyrosination. VASH1 or SVBP
knockdown improved contractility and reduced cellular stiffness in
cardiomyocytes isolated from rats or failing human hearts. I also identify that the
microtubule binding activity of TTL is sufficient to depolymerize the
cardiomyocyte microtubule network; however, only the tyrosination specific
effects of TTL improve myocyte relaxation. This research was published in
Circulation Research with my co-author Christina Chen.

Myocyte microtubule dynamics are influenced by tubulin tyrosination status and
desmin intermediate filaments

The regulation of microtubule dynamics potentially represents an
important intermediate in the formation of the dense microtubule network
observed in disease. However, little is known about the regulation of microtubule
dynamics in the healthy cardiomyocyte. In skeletal myocytes microtubules are
nucleated from golgi elements which contain g-tubulin, a tubulin isoform critical
for microtubule nucleation, and the scaffolding protein, pericentrin.49 Microtubules
grow along the structural protein dystrophin and other microtubules, producing a
well-organized orthogonal network49 In the cardiomyocyte, microtubules are
8

stabilized at the Z-disc and predominantly grow longitudinally from adjacent Zdiscs.50 The mechanism underlying the stabilizing effect of the Z-disc and how
the progressive growth is regulated is unknown.
One potential mechanism underlying the regulation of microtubule
dynamics are tubulin post-translational modifications. Post-translational
modification of tubulin are known to impact microtubule dynamics either through
changes to the biophysical properties of the microtubule or through altered
interaction with microtubule associated proteins51,52. For example, acetylation of
K70 of a tubulin occurs on the luminal surface of the polymerized microtubule.53
Structural studies indicate that acetylation weakens the lateral interactions
between protofilaments53 lowering the microtubule’s flexural rigidity and
subsequently increasing its resistance to breakage54. In contrast, microtubule
detyrosination does not alter the inherent stability of the microtubule; however,
detyrosination reduces the affinity of depolymerizing kinesins for the microtubule
which contributes to the observed relative stability of detyrosinated microtubules.
55

The desmin intermediate filament network is also likely to influence
microtubule dynamics and may stabilize the growing microtubule at the Z-disc. A
recent pre-print indicates that intermediate filaments can directly stabilize
growing microtubules via increased hydrophobic and electrostatic interactions.56
Desmin may also reinforce microtubule stability through interactions along the
length of the microtubule. For example, detyrosinated microtubules are known to
9

preferentially interact with intermediate filaments via the plakin family of
scaffolding proteins57 (and through kinesin-1)58.
In chapter 4 I investigate the impact of tubulin post-translational
modifications and the structural components on the Z-disc of the dynamics of
cardiac microtubules. I find that tyrosinated microtubules are more dynamic,
precluding their ability to grow to subsequent Z-discs. I also find that desmin
intermediate filaments structure and stabilize the growing microtubule network
and directly mediate the formation of microtubule buckles.

10

CHAPTER 2: MICROTUBULES RESIST MYOCYTE
CONTRACTION
Depolymerization of the microtubule network in rat cardiomyocytes improves
contractility independent of the calcium transient
Published in: Caporizzo, M. A., Chen, C. Y., Salomon, A. K., Margulies, K. B., &
Prosser, B. L. (2018). Microtubules provide a viscoelastic resistance to myocyte
motion. Biophysical journal, 115(9), 1796-1807.
Cardiomyocyte microtubules form a longitudinal network that runs perpendicular
to the transverse Z-discs that define the sarcomere. Upon myocyte contraction,
microtubules that are physically coupled to the sarcomere buckle to
accommodate the change in cell shape.32 The resulting buckles visually suggest
that cardiac microtubules may provide elastic resistance to myocyte contraction,
in that microtubules may resist compression while providing a restoring force to
aid in myocyte relaxation. Alternatively, microtubules may provide viscoelastic
resistance where energy is dissipated through physical crosslinks made between
the microtubule and sarcomere. Previous attempts at prescribing a mechanical
role for cardiac microtubules have been inconclusive as measurements of singe
cell stiffness have shown microtubules provide viscous59, elastic60, or no
resistance.61
We sought to definitively provide a mechanical role for microtubules in the
contracting cardiomyocyte. To this end I collected paired calcium and contractility
measurements of freshly isolated adult rat cardiomyocytes with or without an
intact microtubule network. To depolymerize the microtubule network, I treated
11

freshly isolated cardiomyocytes with 10 µM colchicine for 1.5 hours. Myocytes
were then loaded with Flou-4 to allow for quantification of the calcium transient
and electrically stimulated at 1Hz. Colchicine treatment did not affect the calcium
transient as peak calcium levels as well as calcium rise, and decay times were
no different than DMSO controls (Figure 1A). In contrast, colchicine treatment
increased myocyte fractional shortening over a similar timescale as control
myocytes (Figure 1B), resulting in increased peak shortening and relaxation
velocities (Figure 1C). This result suggests that microtubules resist
cardiomyocyte contractility independent of changes to calcium handling.
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Figure 2. Microtubule depolymerization enhances myocyte contractility. (A Left) Normalized
calcium transient (F/Fo) for DMSO control (black) and colchicine-treated (purple) cells and
(Right) peak calcium, time to peak, and decay time determined from individual traces (N = 6
hearts, n = 43 DMSO cells, n = 48 colchicine-treated cells). (B Left) Relative shortening (change
in SL divided by resting SL) with time and (Right) peak shortening, shortening, and relaxation
times from individual traces. (C Left) The average shortening velocity for DMSO- and colchicinetreated RCMs and (Right) Peak shortening and relaxation velocity determined for individual data
points. Statistical significance was determined as *p<0.05, **p < 0.01 or ***p <0.001 compared to
DMSO, Student’s t-test.

Depolymerization of the microtubule network improves contractility of failing
human cardiomyocytes
Published in: Chen, C.Y., Caporizzo, M.A., Bedi, K., Vite, A., Bogush, A.I.,
Robsion, P … Salomon, A. K., …& Prosser, B. L. (2018). Suppression of
detyrosinated microtubules improves cardiomyocyte function in human heart
failure. Nature medicine, 24(8), 1225-1233.

To assess the role that microtubules play in failing human cardiomyocytes,
I worked with Christina Chen to isolate cardiomyocytes from non-failing and
failing human hearts. Failing human hearts included heart failure with preserved
ejection fraction (HFpEF), heart failure with reserved ejection fraction (HFrEF),
dilated cardiomyopathy (DCM), and ischemic cardiomyopathy (ICM). Prior to
treatment, cardiomyocytes isolated from failing hearts exhibited less fractional
shortening with slower contractility (Figure 2A, D). Depolymerization of the
microtubule network by colchicine in cardiomyocytes from non-failing hearts had
a marginal, but significant effect in improving fractional shortening as well as
contraction and relaxation velocities (Figure 2B, E). Colchicine treatment
significantly improved contractility of failing cardiomyocytes as demonstrated by
representative traces from myocytes isolated from DCM and ICM hearts (Figure
13

2C). Specifically, colchicine treatment of failing cardiomyocytes significantly
improved fractional shortening in addition to contraction and relaxation velocities
(Figure 2 D,E).
Taken together, I identified that depolymerization of the microtubule
network with colchicine improves myocyte contractility independent of changes to
the calcium transient. Additional studies led by Matthew Caporizzo and Christina
Chen identified that microtubule depolymerization reduces transverse myocyte
stiffness specifically at fast indentation rates. The rate dependent contribution of
microtubules to myocyte stiffness suggests that the microtubule network is
viscoelastic, because the resistive microtubule-sarcomere interactions become
engaged only a rapid length changes.

14

Figure 3. Depolymerization of the microtubule networking improves contractility of failing
human cardiomyocytes. (A) Average sarcomere shortening from DMSO treated myocytes from
failing (black) and non-failing (gray) hearts. Shortening is shown to normalized resting length.
Effect of colchcine (colch) on cardiomyocytes from (B) non-failing, dilated cardiomyopathy (DCM),
and (C) ischemic cardiomyopathy (ICM). (D) Average velocity traces from non-failing, failing, and
colchicine treated myocytes. (F) Pooled data showing percentage improvement in the indicated
contractile parameters following treatment of non-failing or failing hearts with colch or DMSOtreated cells. Statistical significance was determined via two-sided t-tests as *p<0.05, **p < 0.01
or ***p <0.001 compared to DMSO; #p < 0.05, #p < 0.001, ###p < 0.001 versus non failing.
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CHAPTER 3: DEPLETION OF VASOHIBIN 1 SPEED
CONTRACTION AND RELAXATION IN FAILING HUMAN
CARDIOMYOCYTES
Adapted from article published as: Chen, C. Y*., Salomon, A. K*., Caporizzo, M.
A., Curry, S., Kelly, N. A., Bedi, K., … & Prosser, B. L. (2020). Depletion of
vasohibin 1 speeds contraction and relaxation in failing human cardiomyocytes.
Circulation research, 127(2), e14-e27.
*

Co-authors

Introduction
Heart failure is often characterized by diastolic dysfunction, or inadequate
ventricular filling due to the inability of the myocardium to fully relax. Diastolic
dysfunction is a hallmark of hypertrophic cardiomyopathy (HCM)62 and heart
failure with preserved ejection fraction (HFpEF), diseases often characterized by
prolonged and impaired left ventricular (LV) relaxation, slow LV filling, and
increased diastolic LV stiffness.4 Diastolic dysfunction can be initiated by factors
extrinsic to the cardiomyocyte such as hypertension and fibrosis, or intrinsic
impairments to cardiomyocyte calcium cycling and myofilament calcium
sensitivity.
In addition to mechanisms that directly control sarcomere contraction and
relaxation, myocyte motion can be modulated by the mechanical properties of the
non-sarcomeric cytoskeleton.
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Cardiac microtubules provide viscoelastic resistance to myofilament
shortening and re-lengthening through physical coupling of microtubules to the
myofilaments.32,63 This physical interaction is tuned by detyrosination, a posttranslational modification of the C-terminal tail of α-tubulin (Figure 4A). In human
heart failure (HF), the cardiac microtubule network proliferates and becomes
more detyrosinated, increasing viscous drag on the myofilaments.46 Multiple
recent proteomic and biochemical assessments of patient myocardium suggest
that detyrosinated microtubules are upregulated across the spectrum of endstage HF,46 as well as in patients with aortic stenosis64 or inherited HCM.65
Together, this data implicates microtubule detyrosination as a therapeutic target
to lower stiffness and improve myocyte motion in HF.
Detyrosination can be genetically decreased by overexpression of tubulin
tyrosine ligase (TTL), an enzyme highly specific for tubulin and responsible for
ligating the terminal tyrosine residue back to detyrosinated tubulin.44 Promisingly,
overexpression of TTL in cardiomyocytes from patients with HF reduces
cardiomyocyte stiffness, improves contractility,32,46 and reduces cell stiffness
during diastolic stretch.66 However, the precise mechanism by which TTL
modulates myocyte mechanics is unclear, as beyond its tyrosinating activity, TTL
can also depolymerize microtubules by binding free tubulin dimers, preventing
their incorporation into polymerized microtubules.44,67 Because it is
mechanistically unclear if TTL exerts its effect via changes in microtubule
detyrosination, depolymerization, or both, methods to more specifically alter
17

detyrosination are necessary to fully understand the mechanism of TTL action
and to better define therapeutic targets for HF. Prior to the identification of tubulin
carboxypeptidases responsible for detyrosination, tools to inhibit a detyrosinase
have been limited to sesquiterpene lactones such as parthenolide, which must be
used at high concentrations that elicit off target consequences.46,68
The recent identification of a detyrosinating enzyme complex of vasohibin1 or -2 (VASH1/2) and their obligate partner small vasohibin binding protein
(SVBP) potentially enables the development of more specific approaches to
reduce detyrosination.47,48 However, alternative tubulin carboxypeptidases
beyond VASH exist in other cell types,47 and it remains to be determined if either
VASH1 or VASH2 are active detyrosinases in cardiomyocytes, and whether their
selective inhibition is sufficient to improve contractility. In this study, we identify
the VASH1-SVBP complex as a predominant tubulin carboxypeptidase in
cardiomyocytes, and confirm that genetic depletion of VASH1 is sufficient to
lower stiffness and improve contractility in cardiomyocytes from patients with HF.
Further, we identify tyrosination-dependent and independent effects of TTL
overexpression and find that tyrosination preferentially improves the relaxation
kinetics of cardiomyocytes, and exerts its most profound effects on
cardiomyocytes from patients with HF and diastolic dysfunction.
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Results
A note on human samples
Twenty-two human hearts were used in this study for functional tests. All
patient studies were conducted on explanted human hearts from patients with
non-ischemic heart failure (hypertrophic or dilated cardiomyopathy, HCM or
DCM, respectively). When sufficient samples were available, hearts were further
sub-classified as either heart failure with reduced ejection fraction (HFrEF) for
patients with left-ventricular ejection fraction (LVEF) below 30%, or HFpEF for
those with LVEF above 50% at time of transplant. Non-failing (NF) donor hearts
were used as controls. For relevant clinical characteristics please see Table 1,
and for descriptions of experiments performed on each heart, please see
Appendix Table 2.
Table 1. Summary descriptive statistics of human hearts used in chapter 3
Etiology

No. of hearts

Age (year)

LVMI (g/m2)

LVEF (%)

NF

2M, 4F

54.83 ± 6.09

101.03 ± 8.96

58.33 ± 5.27

HFpEF

3M, 3F

52.17 ± 5.06

150.26 ± 10.96

67.5 ± 2.81

HFrEF

6M, 4F

48.1 ± 3.75

116.18 ± 6.49

18 ± 1.53

Each value is presented as mean ± s.e.m. Abbreviations: F, female; LVMI, left
ventricular mass index; M, male.
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TTL overexpression improves contractility in isolated cardiomyocytes from failing
human hearts independent of changes to the calcium transient
We previously showed that TTL overexpression reduces viscoelasticity
and improves contractility in NF human cardiomyocytes.46 Because the
microtubule network increases in density and becomes highly detyrosinated
during heart disease, we wanted to extend these studies to cardiomyocytes from
failing hearts, and examine any effect of TTL overexpression on calcium
handling. We transduced cardiomyocytes from patients with HF with adenovirus
overexpressing TTL or a control virus (null), and assessed electrically stimulated
[Ca2+]i transients and sarcomere shortening. TTL overexpression robustly
improved myocyte contraction and relaxation kinetics, with no detectable change
to the kinetics or amplitude of the calcium transient (Figure 4B, Appendix Table
2). These results are consistent with the hypothesis that reducing detyrosination
improves the contractility of failing cardiomyocytes through mechanisms
predominantly independent of a change in calcium cycling.
Generation of constructs to isolate TTL tubulin sequestration from tyrosination
Although TTL overexpression reduces the proportion of detyrosinated
microtubules, the precise mechanism by which TTL improves contractility is not
clear, as TTL can depolymerize the microtubule network via sequestration of free
tubulin,44 which is sufficient to improve contractility.69 To isolate effects of TTL
attributable to tubulin sequestration vs. tyrosination, we generated adenovirus
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encoding an established TTL catalytic-dead construct (TTL-E331Q) that binds
tubulin with wildtype kinetics, but cannot enzymatically tyrosinate tubulin.44 We
validated this tool in healthy rat cardiomyocytes, where adenoviral
overexpression of TTL-E331Q to the same level of TTL did not significantly
reduce detyrosinated tubulin (Figure 4C).
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Figure 4. Identification of the primary cardiac detyrosinase and development of tools to
probe the tyrosination cycle. A, Schematic of proposed microtubule tyrosination cycle in
cardiomyocytes. B, Average traces of electrically stimulated [Ca2+]i transients (top) and
sarcomere shortening (bottom) from failing human cardiomyocytes infected with a null (grey) or
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TTL-encoding (blue) adenovirus. Traces depict change in signal normalized to resting
fluorescence (F0) or resting length. Kinetic parameters of calcium transients and sarcomere
shortening are quantified to the right. Statistical significance determined via two-sided t-tests with
Bonferroni correction for two comparisons, unadjusted P value are shown * vs. null. C, Validation
of TTL-E331Q construct. Representative western blot and quantification of TTL, detyrosinated
tubulin (dTyr-tub), α-tubulin (α-tub), and GAPDH levels in whole cell extracts from isolated rat
cardiomyocytes expressing null, TTL, or TTL-E331Q constructs. Statistical significance
determined via one-way analysis of variance (ANOVA) with post-hoc Bonferroni test from
duplicates of N=3 rat hearts, * vs. null. D, Expression profiling of VASH1, VASH2 and SVBP
genes via RT-qPCR of patient myocardial samples. Statistical significance determined via oneway ANOVA with post-hoc Bonferroni test, * vs. NF. E, Expression levels of Vash1 and Vash2 in
isolated rat cardiomyocytes. F, Validation of knockdown (KD) via RT-qPCR quantification of
Vash1, Vash2, and Svbp in rat cardiomyocytes. G, Representative western blot and quantification
of detyrosinated tubulin, α-tubulin, and GAPDH levels from isolated rat cardiomyocytes treated
with different concentrations of adenovirus encoding SVBP or VASH1 KD constructs. Data
presented as fold change from scramble (scram) control. Statistical significance determined via
two-sided Student’s t-tests for RT-qPCR (F) and VASH2 KD western blot (G), and via one-way
ANOVA for VASH1 and SVBP KD western blot, * vs. scram. Data are presented as mean ± s.d. if
not otherwise specified.

VASH1/SVBP is a predominant cardiac tubulin carboxypeptidase
To interrogate detyrosination, independent of any potential microtubule
depolymerization via TTL, we sought to directly manipulate a cardiac
detyrosinase. We conducted experiments to verify if the recently identified VASHSVBP complex is a primary detyrosinase in myocardium, to determine if any
isoform of VASH is dominant, and whether VASH/SVBP expression changes in
disease. Transcriptional profiling of healthy and diseased human myocardium
identified that VASH1 has approximately 15-fold (±5) higher expression level
than VASH2 in NF tissue (Figure 4D). In isolated rat cardiomyocytes, we found
Vash1 to be expressed ~5 fold (±2.2) more than Vash2 (Figure 4E). In diseased
myocardium, VASH1 gene expression was higher in dilated cardiomyopathy
(DCM) and did not significantly change in ischemic cardiomyopathy or HCM,
while VASH2 gene expression was modestly decreased in HF (Figure 4D).
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When comparing the expression of VASH1 to VASH2 across all etiologies of HF,
VASH1 was expressed ~28-50 fold higher than VASH2. SVBP was consistently
expressed at a high level and did not show differential expression with disease.
We also sought to evaluate protein abundance of VASH1/2 and SVBP, but
were aware of the lack of well-validated antibodies for these targets (note the
lack of any such antibodies used in recent publications identifying the role and
structure of these enzymes). To address this, we generated new antibodies that
were validated in parallel with commercial antibodies in vitro (please see
Appendix Figure 1 for details). While the custom VASH1 antibody was indeed
more sensitive and specific than commercially available options, we still were
unable to detect a reliable band in cardiac cell or tissue lysate. Thus, further work
is needed to detect these enzymes, which are likely of relatively low abundance
in the cardiac proteome.

Figure 5: Validation of shRNAs specific for VASH1, VASH2 and SBVP transcripts.
Quantification of western blots from isolated rat cardiomyocytes transduced with shRNAs specific
for VASH1, VASH2 or SVBP probed for (A) detyrosinated tubulin or (B) α-tubulin. Statistical
significance determined via ANOVA with post-hoc Bonferroni test for data from VASH1/SVBP KD
or two-sided t-test for separate data from VASH2 KD experiments, *vs. scram.
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We next depleted VASH1, VASH2, and SVBP in healthy rat
cardiomyocytes to determine if they function as tubulin carboxypeptidases. For
each of these genes, we generated three adenoviruses encoding short hairpin
RNAs (shRNAs) specific for three target sites conserved between rats and
humans. Delivery of each of these shRNAs by adenovirus to isolated rat
cardiomyocytes resulted in a reduction of detyrosinated tubulin, without changing
total tubulin levels (Figure 4G; Figure 5). We selected the shRNAs that resulted
in the most robust and consistent decrease in detyrosinated tubulin levels and
confirmed that they depleted Vash1, Vash2 and Svbp transcripts via RT-qPCR
(Figure 4F). With similar decreases in transcript levels (Figure 4F), VASH1 and
SVBP KD induced an ~55% (± 5) reduction in detyrosinated tubulin while VASH2
KD caused a ~25% (± 6.5%) reduction (Figure 4G). As SVBP depletion inhibits
the functionality of both VASH1 and VASH2,70–72 SVBP depletion would be
predicted to lead to a greater reduction in detyrosinated tubulin than depletion of
VASH1 or VASH2 alone. We did not observe this, which could be due to
incomplete SVBP KD or SVBP-autonomous activity of VASH2, as indicated in a
recent report.73 Regardless, our results support a more prominent role of VASH1
in cardiomyocyte detyrosination, which is consistent with a recent patent74
demonstrating that VASH1 KO robustly reduces detyrosinated tubulin in the
heart, while VASH2 KO has a more modest effect. The fact that TTL
overexpression reduces detyrosinated-tubulin by ~80% (± 5) while VASH1/SVBP
depletion lowers levels by ~55% is consistent with the abundant expression of
TUBA4A in cardiomyocytes,46,48 an α-tubulin isotype translated in its
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detyrosinated form, and thus insensitive to manipulation of a detyrosinase, but
readily tyrosinated by TTL.
Tubulin sequestration by TTL, and not VASH1/SVBP knockdown, decreases
microtubule stability in healthy cardiomyocytes
With these new tools generated, we next sought to determine the effect
that TTL/TTL-E331Q overexpression or VASH1/SVBP knockdown has on the
stability of the microtubule network. Using a fractionation assay that allows for
separation of soluble, free tubulin from polymerized microtubules, we found that
overexpression of TTL (~9 ± 2 fold) in healthy rat cardiomyocytes led to a robust
(~80% ± 5) reduction in detyrosinated tubulin that did not occur with TTL-E331Q
(Figure 6A and 6B). Both TTL and TTL-E331Q overexpression increased the
amount of free tubulin relative to polymerized microtubules (Figure 6A and 6C),
indicating modest depolymerization of the microtubule network. In contrast,
knockdown of either VASH1 or SVBP reduced the level of detyrosinated tubulin
in polymerized microtubules (~40% ± 2), yet the free:polymerized tubulin ratio
remained unchanged (Figure 6A through 6C). These results suggest that tubulin
binding via TTL is sufficient to depolymerize the microtubule network in isolated
rat cardiomyocytes, and that modest reductions in detyrosination alone are not
sufficient to depolymerize microtubules.
We noted that TTL overexpression or knockdown resulted in variable
changes in the ratio of free:polymerized tubulin that seemed to mirror changes in
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detyrosination. Indeed, plotting the change in detyrosinated tubulin from each
experiment against the change in free:polymerized tubulin revealed an inverse
correlation with levels of detyrosination (Figure 6D), suggesting that decreasing
detyrosination may decrease microtubule network stability in cardiomyocytes, but
requires a threshold reduction in detyrosination. This would imply that any
destabilizing effect of VASH1/SVBP depletion would be contingent on a sufficient
initial proportion of detyrosinated microtubules in the network, such as occurs in
HF.

Figure 6. TTL tubulin sequestration, but not detyrosination, depolymerizes microtubules in
healthy cardiomyocytes. A, Representative western blot of free and polymerized tubulin from
isolated rat cardiomyocytes transduced with adenoviruses encoding null, TTL, TTL-E331Q,
scram, VASH1 KD and SVBP KD. Quantification of (B) detyrosinated tubulin level found in the
polymerized fraction and (C) free to polymerized tubulin ratio. Statistical significance determined
via one-way ANOVA with post-hoc Bonferroni test, * vs. null or scram, with duplicates of N=7 rat
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hearts for null and TTL and duplicates of N=4 for TTL-E331Q, scram, VASH1 KD, and SVBP KD.
D, Correlation between detyrosinated tubulin levels found in the polymerized fraction and the
ratio of free:polymerized tubulin.

Effects of VASH1 knockdown and TTL-E331Q overexpression on myocyte
contractility
We next sought to determine how TTL/TTL-E331Q overexpression or
VASH1 knockdown would affect the contractility of isolated cardiomyocytes from
failing and NF hearts. In cardiomyocytes from NF donor hearts, VASH1
knockdown produced modest but consistent speeding of contraction and
relaxation kinetics, and subtle effects on contractile amplitudes (Figure 7A
through 3D; Appendix Table 2). We also interrogated the effect of VASH1
depletion in cardiomyocytes from 6 patients with HF, 3 with HFrEF (systolic
dysfunction), and 3 with HFpEF (diastolic dysfunction). As shown in the average
traces of cardiomyocytes from these hearts transduced with control adenovirus
(Figure 7B), failing heart cells exhibited lower contractile amplitudes and slower
kinetics than NF controls. There was markedly slower relaxation in failing
cardiomyocytes that was particularly evident in HFpEF cardiomyocytes (Figure
7C), consistent with the impaired relaxation implicated in this disease etiology.
On average, relaxation velocity was 2.1-fold and 3.6-fold lower in HFrEF and
HFpEF than in NF controls, respectively (scram groups: NF 1.51 ± 0.056, HFrEF
0.71 ± 0.083, and HFpEF 0.41 ± 0.041 μm/s). VASH1 depletion markedly
improved contractile amplitudes and contraction and relaxation kinetics in failing
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cardiomyocytes, eliciting a 1.6 and 2-fold improvement in relaxation velocity in
HFrEF and HFpEF cardiomyocytes, respectively (VASH1 KD groups: NF 1.79 ±
0.062, HFrEF 1.12 ± 0.099, and HFpEF 0.81 ± 0.065 μm/s; Figure 7A through
7D; Appendix Table 2).

Figure 7. Reducing detyrosination speeds contraction and relaxation of failing human
cardiomyocytes. A, Example of sarcomere shortening trace from myocyte responding to
electrical stimulation and corresponding first derivative identifying key contractile parameters
collected. B, Average traces of sarcomere shortening from cardiomyocytes isolated from NF
donor hearts and from hearts from patients with HFrEF and HFpEF, with or without VASH1 KD.
C, Contraction and relaxation times are quantified and grouped by etiology and experimental
conditions. Statistical significance determined via two-way ANOVA between the effects of etiology
and treatment. P values for significant interactions are shown. For detailed two-way ANOVA
report, see Online Table 3. D through F, Percent improvement in contractile parameters by each
genetic manipulation over null or scram is quantified and grouped by etiology and experimental
conditions. D, statistical significance determined via two-sided Student’s t-tests with Bonferroni
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correction for six comparisons (adjusted α=0.05/6=0.0083), unadjusted P values are shown * vs.
scram and † vs. NF. E and F, Statistical significance determined via two-sided Student’s t-tests
with Bonferroni correction for six comparisons

The effect of SVBP depletion was examined in cardiomyocytes from a
separate subset of 3 failing hearts (2 HFrEF, 1HFpEF), where it elicited similar
improvements in contraction and relaxation kinetics as VASH1 knockdown
(Figure 8C and 8D; Appendix Table 2).

Figure 8. SVBP knockdown improves contractility in both healthy and failing isolated
cardiomyocytes. Average sarcomere shortening traces from electrically stimulated (A) healthy
isolated rat cardiomyocytes and (C) failing cardiomyocytes from patients with heart failure
transfected with adenovirus containing either SVBP KD (blue) or scram (grey) constructs. B and
D, Quantification of kinetic parameters. Statistical significance determined via two-sided t-tests
with Bonferroni correction for two comparisons (adjusted α=0.025), * vs. scram.
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In NF cardiomyocytes, both TTL and TTL-E331Q overexpression
improved most metrics of systolic function compared to cells transduced with
control adenovirus, although improvements in relaxation time appeared to only
be sensitive to TTL, and not to TTL-E331Q (Figure 7C and 7E). This became
more apparent in cardiomyocytes from failing hearts (HFrEF), where both
constructs improved systolic parameters, yet TTL had a significantly greater
effect than its catalytically dead counterpart on relaxation time, and robustly
improved relaxation velocity (Figure 7C and 7F).
Together, this data indicates that 1) relaxation kinetics are particularly
slowed in failing cardiomyocytes; 2) selectively targeting microtubule
detyrosination via either the tyrosinase or detyrosinase is sufficient to robustly
improve relaxation kinetics; 3) the effect of reducing microtubule detyrosination is
most remarkable in failing cardiomyocytes; and 4) the microtubule
depolymerizing activity of TTL is sufficient to augment systolic, but not
necessarily diastolic parameters.
VASH-1 knockdown reduces myocyte stiffness and has negligible effects on
[Ca2+]i transients
Typically, we conduct myocyte contractility assays in the absence of Ca2+
indicator dye, as they can slow contractile kinetics due to Ca2+ buffering and
obscure kinetic phenotypes. For this reason, the [Ca2+]i transient data in Figure
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4B was collected on a separate subset of cardiomyocytes from those evaluated
for contractility. Recognizing that inhibition of tubulin detyrosination with
parthenolide has off target consequences on calcium handling in human
cardiomyocytes,46 we sought to more directly examine the relationship between
calcium handling and contractility after VASH1 knockdown in myocytes. Thus,
cardiomyocytes from a separate subset of 5 hearts were loaded with a low
concentration of the Ca2+ indicator dye fluo-3 and simultaneously assessed for
[Ca2+]i transients and contractility. As shown in the average trace of myocytes
from a HFpEF heart (Figure 8A), VASH1 knockdown robustly improved
fractional shortening, contraction and relaxation speed independent of any
observable change in Ca2+ handling in those same cells. This Ca2+-independent
improvement in contractility was observed in both NF and failing cardiomyocytes
(Figure 9B and 9C).
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Figure 9. VASH1 knockdown reduces myocyte viscoelasticity and improves contractility
independent of changes to the calcium transient. A, Average traces of simultaneously
acquired [Ca2+]i transients and sarcomere shortening from fluo-3 loaded cardiomyocytes isolated
from the heart of patient #1790 with heart failure with preserved ejection fraction (HFpEF). Traces
are normalized to baseline fluorescence (F0) and sarcomere length, respectively. Amplitude and
kinetic parameters from [Ca2+]i transients (B) and sarcomere shortening (C) were quantified
simultaneously in cardiomyocytes isolated from NF or failing hearts with or without VASH1 KD.
Statistical significance determined via two-sided t-tests with Bonferroni correction for three
comparisons (adjusted α=0.05/3=0.017), unadjusted P values are shown * vs. scram of that
etiology. D, Nanoindentation measurements of viscoelasticity. Stiffness (elastic modulus) of
failing cardiomyocytes as a function of probe indentation velocity with or without VASH1 KD.
Quantification of Emin, Emax and viscoelasticity (E∆) in right panels. Statistical significance
determined via two-sided t-tests for three comparisons (adjusted α=0.017), unadjusted P values
are shown *vs. scram. Data are presented as mean ± s.e.m. in (D) left panel.

In the absence of any demonstrable effect on Ca2+ cycling, the observed
improvement of systolic and diastolic kinetics with VASH1 knockdown are
consistent with a reduction of viscoelastic resistance to sarcomere motion
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contributed by detyrosinated microtubules.63 To test this hypothesis, we directly
probed viscoelasticity via transverse nanoindentation of failing human
cardiomyocytes with or without VASH1 knockdown. In response to very slow
deformation, the Young’s modulus of VASH1-depleted cells was unchanged,
suggesting a minimal effect on transverse elasticity (Emin, Figure 9D). Yet at
rates of deformation relevant to the cardiac cycle, VASH1 knockdown reduced
transverse stiffness, with a prominent reduction in peak stiffness at high speeds
of deformation (Emax) and viscoelasticity (E∆, rate-dependent stiffness) in
cardiomyocytes from failing human hearts. Together, these data are consistent
with improved kinetics of failing ventricular cardiomyocytes conferred at least in
part by reductions in viscoelasticity, due to depletion of VASH1 and reduction in
detyrosinated microtubules.
Discussion
From the above data we come to the following conclusions: 1) the VASH1SVBP complex acts as a tubulin carboxypeptidase in cardiomyocytes; 2)
knockdown of VASH1 reduces cardiomyocyte stiffness and improves
contractility, particularly in cardiomyocytes from patients with HF; and 3) targeting
microtubule detyrosination specifically speeds cardiomyocyte relaxation, which
does not require microtubule depolymerization or changes to the Ca2+ transient.
This work identifies new therapeutic targets for the modulation of cardiomyocyte
relaxation and diastolic function.

34

This study represents the first examination of direct suppression of a
tubulin carboxypeptidase in cardiomyocytes. Prior to the discovery of VASHSVBP as a detyrosinating enzyme complex, the putative carboxypeptidase was
commonly inhibited pharmacologically with parthenolide. While effective at high
concentrations, parthenolide enacts multiple off target effects including
alterations in calcium handling46 and cellular signaling cascades.68,75
Detyrosination can be genetically reduced by overexpression of the
tyrosinating enzyme TTL, and like parthenolide, TTL overexpression reduces
stiffness and improves contractility in human cardiomyocytes. Yet the mechanism
of TTL action is confounded by the ability of TTL to depolymerize the microtubule
network through its 1:1 interaction with free tubulin.44,67 While mild
depolymerization of the microtubule network might be acutely beneficial in
improving cardiomyocyte contractility, chronic or gross depolymerization could
lead to trafficking and signaling defects.7,76 A TTL-based therapeutic approach is
further complicated by a reliance on gene therapy to deliver TTL or the unlikely
identification of a TTL agonist. In contrast, small molecule inhibitors of VASH1 or
the VASH-SVBP interaction can be more readily designed based on recent
structural studies of the complex70–72 or identified using high-throughput screens,
potentially facilitating translational studies. The role of VASH1 as a negative
regulator of angiogenesis must be considered, but the vascular architecture of
Vash1 KO mice appears largely unchanged. 77
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A limitation of the current work is the difficulty in quantifying protein levels
of VASH/SVBP, which may be aided by further antibody refinement or targeted
mass-spectrometry approaches. Additionally, protein expression does not speak
to enzymatic activity directly, and little is known about post-translational
regulation of these enzymes and the effect it has on detyrosinase activity.
These results provide the first demonstration of the effects of
VASH1/SVBP inhibition on the intrinsic relaxation and viscoelasticity of isolated
cardiomyocytes. This is a simplified system, and the diastolic pressure-volume
relationship in vivo is influenced by numerous additional factors, including filling
pressures that load and stretch cardiomyocytes. Of note, similar reductions in
viscoelasticity with parthenolide or TTL overexpression equate to increased
compliance of cardiomyocytes upon loaded cell stretch,69 so we surmise the
same will hold true for inhibition of VASH1. The current study prompts future
investigations of the role of VASH1 in animal models of diastolic dysfunction, yet
care must be taken in experimental design.
It is difficult to predict how chronic manipulations of TTL may affect cardiac
function (or how effects will be interpreted), given the numerous potential
consequences of altering microtubule detyrosination,66 for example on
autophagy,78 oxidative stress,7,8 and intracellular trafficking.79–81 Further, it is
unclear whether common murine models of heart failure recapitulate the
cytoskeletal remodeling that occurs in patients with HCM and heart failure.
Studies utilizing small molecule inhibition or rapid, inducible depletion of VASH1
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in models of diastolic dysfunction that recapitulate the patient cytoskeletal
landscape will be most informative.46,64,65
Methods
Human myocardial tissue
Procurement of human myocardial tissue was performed under protocols
and ethical regulations approved by Institutional Review Boards at the University
of Pennsylvania and the Gift-of-Life Donor Program (Pennsylvania, USA) and as
described.46 Briefly, failing human hearts of non-ischemic origin were procured
at the time of orthotropic heart transplantation at the Hospital of the University of
Pennsylvania following informed consent from all participants. Non-failing (NF)
hearts were obtained at the time of organ donation from cadaveric donors. In all
cases, hearts were arrested in situ using ice-cold cardioplegia solution and
transported on wet ice. Whole hearts and dissected left ventricle were weighed to
determine levels of hypertrophy. Failing hearts are etiologically defined by clinical
diagnosis of HF, which is subdivided into HFpEF (ejection fraction > 50%) and
HFrEF (ejection fraction < 30%). Hearts were utilized for a particular experiment
as they arrived until the required sample size was reached for each etiology of
interest (e.g. triplicate quality isolations and experiments for NF, HFpEF and
HFrEF).
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For this study myocytes were isolated from 22 hearts (see method details
below) for functional studies. For further details on classification, descriptive
statistics, and experiments performed on each heart, see Appendix Table 1.
Human left ventricular myocyte isolation and cell culture
Human left ventricular myocytes were isolated as described previously.46
Culture medium consisted of F-10 (1X) Nutrient Mixture (Ham) [+] L-Glutamine
(Life Technologies, 11550-043) supplemented with insulin-transferrin selenium-X
(Gibco, 51500-056), 20 mmol/L HEPES, 1 μg μl-1 primocin (Invivogen, ant-pm-1),
0.4 mmol/L extra CaCl2, 5% FBS, and 25 μmol/L cytochalasin D (Cayman,
11330). Viable myocytes were concentrated by gravity and the proper amount of
medium was added in culture so that neighboring cells were not in direct contact.
Viral constructs were permitted to express for 48 hours with a multiplicity of
infection = 100-200.
Animals
Animal care and procedures were approved and performed in accordance
with the standards set forth by the University of Pennsylvania Institutional Animal
Care and Use Committee and the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health.
Rat cardiomyocyte isolation and culture
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Primary adult ventricular cardiac myocytes were isolated from 6- to 8week-old Sprague Dawley rats as previously described.7 Briefly, the heart was
removed from a rat anesthetized under isoflurane and retrograde-perfused on a
Langendorff apparatus with a collagenase solution. The digested heart was then
minced and triturated using a glass pipette. The resulting supernatant was
separated and centrifuged at 300 revolution per minute (rpm) to isolate
cardiomyocytes which were then resuspended in rat cardiomyocyte media at low
density. Cardiomyocytes were cultured at 37°C and 5% CO2 with 25 μmol/L of
cytochalasin D. The viability of rat cardiomyocytes upon isolation is typically on
the order of 50-75% rod-shaped, electrically excitable cells, and the survivability
for 48hrs of culture is >80% (See Heffler et al.6 for our quantification of
cardiomyocyte morphology in culture). While the viability of human
cardiomyocyte isolations is lower (with more variation between preparations), the
48hr survivability is similar to rat cardiomyocytes, and did not differ between
experimental groups.
Rat cardiomyocyte media: medium 199 (Thermo Fisher 115090) supplemented
with 1x Insulin-transferrin-selenium-X (Gibco 51500056), 1 μg μl-1 primocin
(Invivogen ant-pm-1), 20 mmol/L HEPES at pH 7.4 and 25 μmol/L cytochalasin
D.
Contractility and Calcium transient measurement
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Experiments were performed as previously described.46 Briefly, prior to
contractility measurement, cultured human myocytes were transferred to fresh
warm medium without cytochalasin D. Contractility was measured in a customfabricated cell chamber (IonOptix) mounted on an LSM Zeiss 880 inverted
confocal microscope using either a 40 or 63 X oil 1.4 numerical aperture
objective and transmitted light camera (IonOptix MyoCam-S). Experiments were
conducted at room temperature and field stimulation was provided at 0.5 Hz with
a cell stimulator (MyoPacer, IonOptix). After 10-30 seconds of pacing to achieve
steady state, five traces were recorded and analyzed. Sarcomere length was
measured optically by Fourier transform analysis (IonWizard, IonOptix).
For simultaneous calcium and contractility measurement, myocytes were
incubated with 2 μmol/L fluo-3-acetoxymethyl ester (Invitrogen) on rocker for 10
minutes at room temperature, then enriched by gravity for 5 minutes and
replenished with fresh warm medium without cytochalasin D. Sarcomere length
and fluo3 fluorescence were measured in a custom-fabricated cell chamber
(IonOptix) mounted on a Zeiss inverted microscope using a 40 X water 1.2
numerical aperture objective and CCD video camera (MyoCam-S3) coupling to a
cell framing adaptor that connects to a photomultiplier tube (PMT400 SubSystem, IonOptix). Cell framing box for fluorescence detection was set at a fixed
size. Fluorescence level of a blank area in the dish was recorded to account for
background noise. Myocytes were electrically paced at 0.5 Hz at room
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temperature and both sarcomere length and fluorescence counts were recorded
simultaneously for five steady-state transients.
Generation of short hairpin RNAs
Adenoviruses encoding shVASH and shSVBP constructs were generated
and produced in a similar manner as previously described3, but directed towards
single target sites under the U6 promotor in three separate viruses. Target sites
for VASH1: sh1: gctgcagtacaatcacacagg, sh2: gggacacagttctttgaaatt, sh3:
gggaatttacctcaccaacag; for SVBP: sh1: gacaaagagcagagatctatg, sh2:
gcagcagcagtttgatgagtt, sh3: gcagcagtttgatgagttctg; for VASH2: sh1:
gtcaagaaggtcaagattggg, sh2: ggtcaagattgggctgtacgt, sh3: gtcaagattgggctgtacgt.
eBFP2 was used as a marker of transduction. For data in the primary figures,
VASH1 sh1, SVBP sh3, and VASH2 sh2 were utilized.
RNA isolation, cDNA synthesis, and RT-qPCR
RNA was isolated from cardiomyocytes using RNAzol RT (Molecular
Research Center RN190) following the manufacturer's instructions. Briefly,
cardiomyocytes were lysed in RNAzol RT reagent. One ml of the lysate was
combined with 0.4 ml of water and shaken vigorously for 15 seconds and stored
for 15 minutes at room temperature. Samples were then centrifuged at 12,000 g
for 15 minutes. The supernatant was removed to a new tube and mixed with one
volume of isopropanol, stored at room temperature for 10 minutes, then
centrifuged at 12,000 g for 10 minutes. The RNA pellet was then washed with
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75% ethanol two times and solubilized in RNase-free water. RNA concentration
was determined using a Nanodrop (ThermoFisher) and 2μg RNA was reverse
transcribed using cDNA synthesis kit (TaKaRa #6110A or SuperScript IV Thermo
Fisher #18091150) following manufacturer’s instructions. Twenty ng of cDNA
template was then used to conduct RT-qPCR in three technical replicates. For
Vash1 and Svbp knockdown data sets, Powerup SYBR green master mix
(#A25742, Thermo Fisher) was used with the following primers and thermocycle
conditions: Gapdh (F-5’-CGTGCCGCCTGGAGAAAC-3’ and R-5'TGGGAGTTGCTGTTGAAGTCG-3’), Vash1 (F-5’TCGTCGGCTGGAAAGTAGGCAC-3’ and R-5’TCGTCGGCTGGAAAGTAGGCAC-3’), Svbp (F-5’AACCAGCCTTCAGAGTGGAGAAGG-3’ and R-5’GCTCCGTCATGACTCTGTTGAGAGC-3’); Polymerase activation at 95 ˚C for 10
minutes and 40 cycles of denaturation at 95˚C for 15 seconds and
annealing/extension at 60˚C for 1 minutes. For Vash2 knockdown and relative
transcript levels of Vash1 and Vash2 in rat myocytes, PrimeTime gene
expression master mix (#1055772) with the following primers/probes and
thermocycle conditions: Vash2 (probe 5’-/56FAM/TCAAGATCT/ZEN/TCATCCGCATGTCCCTG/3IABkFQ/-3’, F-5’GAAGCAACTTGTCCTCAATGTC-3’ and R-5’-GGATTCTCACTTGGGTTGGAG3’) (assay name Rn.PT.58.45226291); Vash1 (probe 5’-56FAM/TGCCTACTT/ZEN/TCCAGCCGACAACG/3IABkFQ/-3’, F-5’GCCCAAGATTCCCATACCAA-3’ and R-5’-ACTGTGTCCCTGTGTGATTG-3’)
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(assay name Rn.PT.58.37363926); Gapdh (probe 5’-/56FAM/CAGCACCAG/ZEN/CATCACCCCATTTG/3IABkFQ/-3’, F-5’AACCCATCACCATCTTCCAG-3’ and R-5’-CCAGTAGACTCCACGACATAC-3’)
(assay name Rn.PT.39a.11180736.g) (Integrated DNA Technologies);
Polymerase activation at 95 ˚C for 3 minutes and 40 cycles of denaturation at
95˚C for 15 seconds and annealing/extension at 60˚C for 1 minutes. Cycle
threshold (Ct) values were quantified on a QuantStudio 3 Real Time PCR system
(ThermoFisher). Gene expression fold change was quantified using the deltadelta Ct method normalized to Gapdh and the scram group.
For RT-qPCR experiments in human samples, total RNA was extracted
from septal myectomies of HCM patients (N=19), from explanted hearts of DCM
patients (N=10) and from ischemic cardiomyopathy (ICM, N=10) patients as well
as from NF human heart tissue not suitable for transplantation or from donors
that did not die from cardiac disease but of another cause (NF, N=10-11) using
the SV Total RNA Isolation Kit (Promega) according to the manufacturer’s
instructions and as described previously.82 RNA concentration and purity was
determined photometrically using the Nanodrop ND-1000. RNA was reversetranscribed to cDNA using the Superscript III (Invitrogen) kit. Subsequently, RTqPCR was performed using the Maxima SYBR Green/ROX qPCR Master Mix
(Thermo Scientific) and the specific following primers and thermocycle
conditions: GAPDH (F-5’- ATGTTCGTCATGGGTGTGAA -3’ and R-5’TGAGTCCTTCCACGATACCA -3’), VASH1 (F-5’43

AGAGGAAGGGGAAGAGGACC-3’ and R-5’- GTAGGCACACTCGGTATGGG 3’), VASH2 (F-5’- GTTCCACGTCAACAAGAGCG and R-5’CGACAGCCTGTAGTTTGGGA -3’), SVBP (F-5’CAGCAGAGTTGAGAAGGCCA -3’ and R-5’- CCAGGAGGCTGCATCTGTTT 3’); Polymerase activation at 95 ˚C for 10 minutes and 40 cycles of denaturation
at 95˚C for 15 seconds and annealing/extension at 60˚C for 1 minutes. Relative
gene expression of VASH1, VASH2 and SVBP was calculated using the delta Ct
method (with a formula 2^ (-delta Ct)) normalized to GAPDH.

Microtubule fractionation assay
Isolated rat cardiomyocytes were pelleted by gravity, washed with warm
microtubule stabilizing buffer containing 0.1 mol/L PIPES (pH 6.8), 2mmol/L
EGTA, 0.1 mmol/L EDTA, 0.5 mmol/L MgCl2, 20% glycerol, and centrifuged at
300 rpm for 2 minutes. The resulting pellet was resuspended in 150 µl
microtubule-stabilizing buffer supplemented with 0.1% Triton X-100 and 1X
protease and phosphatase Inhibitor cocktail (Cell Signaling #5872S) and
incubated for 30 minutes at 37 °C. Next, cells were centrifuged at 300 rpm for 2
minutes and the supernatant was collected as the free tubulin fraction. The
resulting pellet was resuspended in 150 µl RIPA buffer (Cayman #10010263)
supplemented with extra 0.8% SDS, disrupted by pipetting every 15 minutes on
ice for 1 hour, then boiled at 100 °C for 3 minutes. Finally, the fraction was
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centrifuged at 12,000 g for 2 minutes and the supernatant was collected as the
polymerized fraction.
Western blot
For whole cell protein extraction, isolated rat cardiomyocytes were lysed in
RIPA buffer (Cayman #10010263) supplemented with protease and phosphatase
Inhibitor cocktail (Cell Signaling #5872S) on ice for 1 hour. The supernatant was
collected and combined with 4X loading dye (Li-COR #928-40004),
supplemented with 10% 2-mercaptoethonol, and boiled for 8 minutes. The
resulting lysate was resolved on SDS-PAGE gel and protein was blotted to
nitrocellulose membrane (Li-COR #926-31902) with mini Trans-Blot Cell (BioRad). Membranes were blocked for an hour in Odyssey Blocking Buffer (TBS)
(LI-COR #927-50000) and probed with corresponding primary antibodies
overnight at 4 °C. Membranes were rinsed with TBS containing 0.5% Tween 20
(TBST) three times and incubated with secondary antibodies TBS supplemented
with extra 0.2% Tween 20 for 1 hour at room temperature. Membranes were
washed again with TBST (0.5% Tween 20) and imaged on an Odyssey Imager.
Image analysis was performed using Image Studio Lite software (LI-COR). All
samples were run in duplicates and analyzed in reference to GAPDH.
Antibodies and labels
Detyrosinated tubulin; rabbit polyclonal (Abcam ab48389); western blot: 1: 1,000.
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Alpha tubulin; mouse monoclonal, clone DM1A (Cell Signaling #3873); western
blot: 1:1,000
TTL; rabbit polyclonal (Proteintech 13618-1-AP); western blot: 1:500.
GAPDH; mouse monoclonal (VWR GenScript A01622-40); western blot: 1:1,000.
IRDye 800CW Donkey anti-Mouse IgG (H + L) (LI-COR 925-32212); western
blot: 1:10,000.
IRDye 680RD Donkey anti-Rabbit IgG (H + L) (LI-COR 925-68073); western blot:
1:10,000.
IRDye 680RD Donkey anti-Mouse IgG (H + L) (LI-COR 926-68072); western blot:
1:10,000.
IRDye 800CW Donkey anti-Rabbit IgG (H + L) (LI-COR 926-32213); western
blot: 1:10,000.
VASH1; rabbit polyclonal (Abcam ab199732); western blot 1:5000–1:1000
A novel antibody for human and mouse VASH1 (named anti-VASH1 Gre)
was produced in rabbits by using a peptide CRIRGATDLPKIPIPSVPTFQPTTPV-NH2 (corresponding to exposed region of the
protein, see Wang, Bosc and Choi et al.)70 linked at the N-terminal to the keyhole
limpet hemocyanin protein via the cysteine. Sera from rabbits were purified on
the respective peptides. Validation of these antibodies was performed in
HEK293T cells protein extracts (see Appendix Figure 1). HEK293T cultures and
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transfections, as well as SDS-PAGE and immunoblots, were performed as in
Aillaud et al.48
Co-immunoprecipitation (co-IP)
Isolated rat cardiomyocytes were lysed in IP buffer containing Tris
50mmol/L pH 8, NaCL 150mmol/L, NP40 1% and protease inhibitor cocktail (Cell
Signaling #5872S) on ice for 30 minutes with pipetting every 10 minutes. Protein
concentration was quantified using Braford dye reagent (Bio-Rad #5000205).
Equal amount of protein (1.5 mg) from each sample was incubated with 6.5μg of
anti-SVBP (Gre) and 10μl of Dynabeads protein G (Invitrogen 10004D, rinsed
four times with ice-cold PBS before used), mixed on a tube revolver (Thermo
Fisher #11-676-341F5). Negative controls for co-IP were run with Rabbit IgG
(6.5μg) or without antibody. After overnight incubation at 4˚C, beads were rinsed
with IP buffer for four times and eluted at room temperature using 30μl 1X Laemli
buffer (Bio-Rad) supplemented with 2-mercaptoethonol. Elution supernatant was
then transferred to fresh tubes and heated at 70˚C for 5 min. Fifteen μl of the
elution from co-IP and whole cells lysates were used in western blot, performed
as described above except the followings. Blots were stained with anti-VASH1
(Gre) at 1:1,000 at 4˚C overnight and a secondary antibody against native rabbit
IgG at 1:1,000 (TrueBlot anti-rabbit IgG HRP from Rockland #18-8816-31) at
room temperature for 1 hour. Blots were developed using a chemiluminescent
substrate (West Pico Plus, Thermo Fisher #34577) and autoradiography film
(Hyblot CL #E3012).
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Nanoindentation
Mechanical properties at the microscopic scale were measured using
nanoindentation69 (Piuma Chiaro, Optics11, The Netherlands). Freshly isolated
human myocytes were attached to glass bottom dishes coated with MyoTak7 in
normal Tyrode’s solution containing 140 mmol/L NaCl, 0.5mmol/L MgCl2, 0.33
mmol/L NaH2PO4, 5 mmol/L HEPES, 5.5 mmol/L glucose, 1 mmol/L CaCl2, 5
mmol/L KCl, pH to 7.4 at room temperature. A spherical nano-indentation probe
with a radius of 3.05 μm and a stiffness of 0.026 N m−1 was used. Myocytes were
indented to a depth of 1.5–3.5 μm with velocities of 0.1, 0.25, 0.5, 1.0, 2.0, 5.0,
10.0, 20.0, 50.0, 100.0, and 150.0 μm s−1. The tip was held in this indentation
depth for 1 s, and retracted over 2 s. The Young’s moduli were calculated
automatically by the software, by fitting the force versus indentation curve to the
Hertz equation.
Statistics
Statistical analysis and graphing were performed using OrginPro software
(OriginLabs). Values are presented as mean ± s.e.m. in line graphs and bar
graphs (Figure 3D through F; Figure 4D), and when stated in the results. For box
plots, box represents 25th to 75th percentiles, the whiskers 1 s.d. and mean line.
Data was checked for normality via Kolmogorov Smirnov test within OriginPro. All
experiments were replicated in multiple rat or human hearts (biologically
independent samples/independent experiments) for each condition, indicated by
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the N number in each figure and figure legend. The exact n values used to
calculate statistics and the statistical tests for significance are stated in individual
graphs or figure legends. Two-sided t-tests were used to determined statistical
significance between experimental conditions vs. control (Figure 4F; Figure 4G
VASH2 KD). One-way analysis of variance (ANOVA) (Figure 4C and 4D; Figure
6B and 6C) or two-way ANOVA (Figure 7C) with post-hoc Bonferroni test.
Given that multiple comparisons were both repetitive and restricted and could
increase the chance of type 1 error (testing multiple parameters derived from one
experiment e.g. contractility), the Bonferroni correction was applied after twosided t-tests to adjust the significance threshold by dividing it with the number of
tests, as described in each figure legend where appropriate, and unadjusted P
values are reported in the figures (Figure 4B; Figure 7D through F; Figure 7B
through 7D).
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CHAPTER 4: DESMIN INTERMEDIATE FILAMENTS AND
TUBULIN DETYROSINATION STABLIZE GROWING
MICROTUBULES AT THE CARDIOMYOCYTE Z-DISC
Adapted from manuscript currently in review for publication in eLife: Salomon
A.K., Okami N., Heffler, J., Lee JJ., Robison P., Bogush AI., Prosser BL. (2021).
Desmin intermediate filaments and tubulin detyrosination stabilize growing
microtubules in the cardiomyocyte.
Introduction
Microtubules are polymers of ⍺- and β-tubulin that are characterized by
cyclical transitions between polymerization and depolymerization, a behavior
called dynamic instability12. Tuning this dynamic behavior confers unique
functionality to specific sub-populations of microtubules83. Control of microtubule
dynamics is cell type- and context-specific and can occur either by modulating
polymer addition or subtraction at the ends, or through lateral interaction with the
microtubule polymer17. The temporal and spatial control of dynamics can be
tuned by post-translational modification of tubulin, which in turn affects the
biophysical properties of the microtubule and interactions with microtubule
associated proteins (MAPs)84. For example, detyrosination, the post translational
removal of the C-terminal tyrosine residue on ⍺-tubulin, has been shown to
increase microtubule stability in mitotic cells by preventing their interaction with
depolymerizing MAPs55.
In the cardiomyocyte, microtubules fulfill both canonical roles in
intracellular trafficking and organelle positioning66, as well as non-canonical
functions matched to the unique demands of working myocytes. In the interior of
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the myocyte, microtubules form a predominantly longitudinal network that runs
perpendicular to the transverse Z-discs that define the sarcomere, the basic
contractile unit of muscle (Figure 10A). Sub-populations of microtubules form
physical connections with the Z-disc that serve as lateral reinforcements along
the length of the microtubule32. Upon stimulation and sarcomere shortening,
these physically coupled microtubules buckle at short stereotypical wavelengths
between sarcomeres to resist the change in myocyte length32. The physical
ramifications of these reinforced microtubules for the myocyte are significant, as
reinforced microtubules can resist 1000x more force than uncoupled
microtubules30,85. This viscoelastic resistance becomes particularly problematic in
heart failure, where proliferation of longitudinal, coupled microtubules stiffens the
cardiomyocyte and impairs myocyte motion46.
Physical coupling of the microtubule to the sarcomere is tuned by
detyrosination. Genetic reduction of detyrosination by overexpression of tubulin
tyrosine ligase (TTL), the enzyme responsible for ligating the terminal tyrosine
residue on detyrosinated tubulin, reduces sarcomeric buckling and the
viscoelastic resistance provided by microtubules, increasing myocyte
contractility46. Tyrosination status also governs microtubule-dependent
mechanotransduction in muscle that regulates downstream second messengers
and is implicated in myopathic states 8. Given its ability to lower stiffness and
improve the function of myocardium from patients with heart failure46, tyrosination
is under pursuit as a novel therapeutic approach. Yet how detyrosination
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promotes the interaction of microtubules with the sarcomere to mediate their
mechanical impact remains poorly understood.
Several observations suggest this interaction may be mediated at least in
part through desmin intermediate filaments that wrap around the Z-disk.
Detyrosination promotes microtubule interaction with intermediate filaments32,86,
and in the absence of desmin, microtubules are disorganized and detyrosination
no longer alters myocyte mechanics32. Additionally, a recent pre-print indicates
that intermediate filaments can directly stabilize dynamic microtubules in vitro56.
Despite this evidence, the effects of desmin or detyrosination on the
dynamics of cardiomyocyte microtubules have not been investigated. We
hypothesized that desmin may serve to stabilize growing microtubules at the Zdisk, which would represent an important intermediary in laterally reinforcing the
network and coupling microtubules to the sarcomere. Here, using a combination
of genetic manipulations, biochemical assays, and direct live-cell observation of
dynamic microtubules, we directly interrogated the effect of tyrosination status
and desmin depletion on microtubule dynamics. We find that desmin dictates the
spatial organization of microtubule dynamics and that growing microtubules are
stabilized at the Z-disc in a desmin-dependent fashion. Additionally, we find that
tyrosinated microtubules are more dynamic, a characteristic that precludes their
ability to efficiently grow between adjacent sarcomeres and form stabilizing
interactions at the Z-disk. These findings provide insight into the organizing
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principles of myocyte cytoarchitecture and into the mechanism of action for
therapeutic strategies that target detyrosinated microtubules.
Results
Tyrosination alters the dynamics of the microtubule network
We first sought to determine the effect of detyrosination on the dynamics
of the cardiomyocyte microtubule network. To reduce detyrosination, we utilized
adenoviral delivery of TTL into isolated adult rat cardiomyocytes32. TTL binds
and tyrosinates tubulin in a 1:1 complex, and so we also utilized adenoviral
delivery of TTL-E331Q (E331Q), a verified catalytically dead mutant of TTL14, to
separate effects of tubulin tyrosination from tubulin sequestration. We have
previously confirmed that TTL overexpression under identical conditions reduces
detyrosination below 25% of initial levels, while TTL-E331Q does not significantly
affect detyrosination levels with similar overexpression42. To specifically quantify
the effects of reducing detyrosination on the dynamic microtubule population, we
adapted a subcellular fractionation assay from Fasset et al., 200987 that allowed
us to separate free tubulin from polymerized tubulin in the dynamic (i.e. coldsensitive) microtubule pool (Figure 10B).
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Figure 10. Tyrosination specifically alters microtubule stability. A Left, Schematic depicting
detyrosinated microtubules (orange) buckling due to physical coupling with desmin at the Z-disc.
Uncoupled tyrosinated microtubules (blue) do not buckle32. Right, Detyrosination and Acetylation
cycles. B Overview of the cell fractionation assay adapted from Fasset et al. 87 that allows for
separation of free tubulin and polymerized microtubules within the dynamic tubulin pool. C
Representative western blot (top) and quantification (bottom) of α-tubulin, detyrosinated (dTyr)
tubulin, and GAPDH in free and cold-sensitive microtubule fractions from adult rat
cardiomyocytes infected with either null, TTL, or TTL-E331Q adenovirus. Detyrosinated tubulin
values normalized to α-tubulin in cold-sensitive fraction. D Representative western blot (top) and
quantification (bottom) of α-tubulin, acetylated tubulin, and GAPDH in whole-cell lysate from null,
TTL, or E331Q expressing myocytes. E Validation of HDAC6 and αTAT1 constructs and
Tubastatin a (TubA) treatment. Representative western blot (top) and quantification (bottom) of
b-tubulin, acetylated tubulin, and GAPDH in whole-cell lysate from adult rat cardiomyocytes
infected with HDAC6, αTAT1, or null adenovirus or treated with 1 µM TubA or DMSO overnight.
F Representative western blot (top) and quantification (bottom) of α-tubulin, dTyr, and GAPDH in
whole cell lysate from adult rat cardiomyocytes infected with HDAC6, αTAT1, or null adenovirus
or treated with 1 µM TubA or DMSO overnight. G Representative western blot (top) and
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quantification (bottom) of b-tubulin, acetylated tubulin, and GAPDH in free and polymerized
dynamic fractions. Lysate from myocytes infected with HDAC6, αTAT1, or null adenovirus or
treated with 1 µM TubA or DMSO overnight. H Relationship between detyrosinated tubulin levels
and acetylated tubulin in lysate from cardiomyocytes infected with Null, TTL, E331Q, shTTL,
shVASH1, shSVBP, or shDes adenovirus. Western blot data points represent technical replicates
(2 from each biological replicate) normalized to their respective controls (N=4 in C+F; N=3 in D,
E, G). Statistical significance determined via two-sample T test with alpha adjusted for multiple
comparisons. Data are presented as mean±SEM unless otherwise specified.

Expression of TTL, but not E331Q, resulted in significantly less
detyrosinated tubulin in the dynamic microtubule pool (Figure 10C). Further, only
TTL expression shifted tubulin away from the polymerized fraction towards the
free tubulin fraction, resulting in an increased ratio of free: polymerized tubulin
(Figure 10C, Figure 11A). This suggests that tyrosination effects the cycling of
tubulin within the dynamic microtubule pool. If indeed tyrosinated microtubules
are more dynamic, then levels of acetylation, a canonical marker of long-lived
microtubules88, should also be decreased by TTL. Consistent with this, TTL, but
not E331Q, led to a robust reduction in levels of microtubule acetylation,
suggesting that tyrosination reduces microtubule lifetime in the cardiomyocyte
(Fig 10D).
As acetylation itself is linked to microtubule stability53,89, the TTLdependent change in the dynamic microtubule pool (Fig 10C) could be directly
related to tyrosination or secondary to the associated reduction in acetylation
(Fig 10D). To discriminate between these two hypotheses, we directly modulated
acetylation. To this end, we developed adenoviral constructs encoding histone
deacetylase 6 (HDAC6) and α tubulin acetyltransferase 1 (αTAT1). HDAC6
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expression reduced total microtubule acetylation to 25% of initial levels (Fig 10E)
and αTAT1 expression increased acetylation 12-fold (Fig 10E). Because αTAT1
has been shown to modulate microtubule dynamics independent of enzymatic
activity90, we also used a pharmacological inhibitor of HDAC6, Tubastatin A
(TubA) to increase acetylation through an orthogonal approach (Fig 10E). Having
validated robust tools to modulate acetylation, we next determined the effect of
acetylation on the dynamic microtubule pool utilizing the same fractionation
assay. HDAC6 expression resulted in less acetylation in the cold-sensitive
fraction while both αTAT1 expression and TubA treatment increased levels of
acetylated tubulin. Neither genetic methods to increase or decrease acetylation
altered the free:polymerized tubulin (Fig 1G, S. Fig 1B); however, TubA
treatment modestly increased the free:polymerized tubulin ratio, suggesting that
while microtubule dynamics are likely unaffected by changing levels of
acetylation, the presence of HDAC6 protein may affect microtubule dynamics as
observed previously91. Given that modulating tyrosination altered levels of
acetylation (Fig 1D), we also asked whether this relationship was reciprocal.
However, whole cell levels of detyrosination were largely unaffected by
modulating acetylation (Fig 1F), except for a modest increase with HDAC6
expression that may be related to HDAC6 association with microtubules
increasing their stability and availability for detyrosination91.
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Figure 11. Quantification of free and polymerized tubulin fractions presented in figure 10.
A Representative western blot (top) and quantification (bottom) for ɑ-tubulin, dTyr tubulin, and
GAPDH in free and cold-sensitive fractions from rat cardiomyocytes infected with null, TTL, or
E331Q adenovirus. B Representative western blot (top) and quantification (bottom) for ɑtubulin, dTyr tubulin, and GAPDH in free and cold-sensitive fractions from rat cardiomyocytes
either infected with null, HDAC, or ATAT1 adenovirus or treated with DMSO or TubA. Statistical
significance determined via ANOVA with post hoc Bonferroni test.

Tyrosination increases catastrophes of growing microtubules
I next wanted to more precisely quantify the effects of tyrosination on the
dynamics of individual microtubules. Microtubule dynamics (Figure 12A) are
characterized by their rates of growth (polymerization) and shrinkage
(depolymerization) as well as the frequency of transitions between these two
states. Events are categorized as catastrophes (transitions from growth to
shrinkage), rescues (transitions from shrinkage to growth), and pauses (neither
growth nor shrinkage). We directly observed the microtubule plus-ends by timelapse imaging of a fluorescent end-binding protein 3 (EB3-GFP) construct
expressed via adenovirus in isolated rat cardiomyocytes (Movie 1 in Appendix).
By creating kymographs from these videos, we were able to quantify dynamic
events (rescue, catastrophe, and pause) in addition to microtubule growth and
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shrinkage kinetics (Fig 12B). We harnessed off-target EB3-GFP Z-disc
localization to characterize dynamic events as occurring on or off the Z-disc, as
in Drum et al.50 As we noted higher variability in measurements from one cell
isolation to another than between cells from the same isolation, experimental
data were normalized to control data that were acquired from the same animals.

Figure 12. Tyrosinated microtubules are more dynamic. A Schematic of microtubule dynamic
events. B Representative kymographs from cardiomyocytes infected with EB3-GFP plus null, TTL
or E331Q adenovirus. Arrowheads denote Z-discs. C Number of initiations, rescues, pauses, and
catastrophes that occur on and off the Z-disc in isolated cardiomyocytes infected with null
adenovirus. D Cell-wide catastrophe (left) and pause (right) frequency in myocytes infected with
null, TTL, or E331Q adenovirus. E Number of catastrophes (left) and pauses (right) that occur on
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and off the Z-disc in myocytes infected with null (black), TTL (blue), or E331Q (yellow)
adenovirus. F Gross measurements of microtubule dynamics. Tortuosity, the distance a
microtubule grows divided by its displacement (left), and number of catastrophes in relation to
number of successful Z-disk crossing (right), in myocytes infected with null, TTL, or E331Q
adenovirus. G Frequency distribution of average microtubule growth displacement, duration, and
velocity in myocytes infected with null, TTL, or E331Q adenovirus. Data are normalized to the
average null value for the corresponding experiment. Statistical significance was determined with
Kruskal-Wallis ANOVA with post-hoc test. Data are presented as mean±SEM unless otherwise
specified.

We began with multiple control experiments. Although EB interaction is
thought to be unaffected by microtubule detyrosination92, we wanted to validate
that EB3 labeling of microtubules did not systematically differ with TTL
expression. EB3 fluorescence intensity along the length and at the tip of the
microtubule was unchanged in control, TTL or E331Q expressing cells (Figure
13A), indicating that EB3 expression or labeling of microtubules was not altered
by our experimental interventions.
As adult ventricular cardiomyocytes are normally paced in vivo but
quiescent in vitro, we sought to determine whether electrical pacing and evoked
contractions would overtly alter microtubule dynamics. To this end, we timed the
imaging of EB3 puncta to occur during the diastolic rest interval between each
contraction of cardiomyocytes that were electrically paced at 0.5Hz. Internally
controlled, pre- and post-comparisons of microtubule dynamics before and during
electrical stimulation showed no significant effect of stimulation on microtubule
dynamic events or growth kinetics in rat cardiomyocytes (Figure 13B). As such,
for the remainder of this study we interrogated quiescent cardiomyocytes to
minimize movement artifacts.
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Figure 13. Supporting data for figure 12. A Background (left) EB3-GFP fluorescence intensity,
EB3 tip fluorescence intensity (center) and the ratio of EB3 tip fluorescence intensity to
microtubule EB3 intensity (right) in isolated rat cardiomyocytes co-infected with null, TTL, or
E331Q adenovirus. Statistical significance determined via ANOVA with post hoc Bonferroni test.
B Representative EB3-GFP kymograph from isolated rat cardiomyocyte before and after 0.5 Hz
electrical stimulation. C Quantification of catastrophe frequency, rescue frequency, microtubule
growth displacement and growth velocity before and after electrical stimulation. D To reduce
levels of detyrosination in this study we relied on overexpression of TTL, which is known to
associate with the free a/b tubulin heterodimer in a 1:1 complex with a Kd of 1 µM44. Due to the
nature of this interaction, TTL overexpression can decrease the amount of “polymerizationcompetent” tubulin, leading to a decrease of in vitro microtubule polymerization44. The
relationship between free tubulin concentration and microtubule polymerization is described as a
simple 1D model below, where ng is the velocity of microtubule growth, d is the dimer length
(assumed to be 8 nm), kon is the tubulin dimer association constant per protofilament (assumed to
be 4.8 µM-1s-1 ) 30, koff is the tubulin dissociation rate constant per protofilament (assumed to be
15s-1 ) 30 , and [Tb] is the concentration of free tubulin51.
𝜈! = 𝑑$𝑘"# [𝑇𝑏] − 𝑘"$$ ,.
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Solving for the equation of the line at a physiologic tubulin concentration of 5µM provides a
theoretical value of 4.32 µm s-1 for growth velocity. Using the Kd value for TTL-tubulin interaction
at a tubulin concentration of 5µM suggests that an 8-fold overexpression of TTL 42will produce 0.2
µM of TTL-tubulin complex. If we assume that tubulin bound to TTL cannot be polymerized, then
only 4.8 µM of free tubulin is polymerization-competent at any time. This change in
polymerization-competent tubulin would lead to ~10% decrease in growth velocity. We did not
observe an effect of E331Q on microtubule growth kinetics or on event frequency suggesting that
the local tubulin concentration at the microtubule plus-tip is unaffected by the sequestration
activity of TTL. Statistical significance determined via 2-sided t test.

Under basal conditions, we observed a stark spatial bias in microtubule
dynamic behavior, similar to that observed by Drum et al50. The initiation of
microtubule growth, as well as pausing of growth, predominantly occurred on the
Z-disc (Figure 12C). Conversely, catastrophes predominantly occurred off the Zdisc, while rescue from catastrophe again occurred more frequently at the Z-disc.
As exemplified in Movies 1-2 (in the appendix), in control (AdV-null) expressing
myocytes microtubules tend to grow iteratively from one Z-disk to another, often
pausing at each Z-disk region. If a microtubule undergoes catastrophe before
reaching a Z-disk, it tends to shrink to a previous Z-disk, where rescue is more
likely to occur. These data suggest factors at the Z-disc region strongly bias
microtubule behavior and support the initialization as well as stabilization of
growing microtubules.
We next interrogated the role of tyrosination. As seen in Movie 3 (in the
appendix), microtubules in TTL treated cells also initiated growth at the Z-disk,
but often had shorter runs and underwent catastrophe prior to reaching a
subsequent Z-disk. Consistently, TTL overexpression significantly increased the
frequency of catastrophes, while tending to reduce the frequency of pausing
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(Figure 12B and D). E331Q expression did not alter event frequency (Movie 4 in
the appendix), suggesting a tyrosination-specific effect on microtubule dynamics.
Further examination of spatial dynamics revealed that TTL similarly increased the
number of catastrophes both on and off the Z-disc while reducing the number of
pauses specifically on the Z-disc (Figure 12E). As a readout of inefficient growth,
TTL increased microtubule tortuosity, the ratio of growth distance to growth
displacement (Figure 12F). Combined, the lack of stabilization at the Z-disc and
more frequent catastrophes resulted in tyrosinated microtubules breaking down
~4 fold as often before successfully crossing a Z-disk when compared to either
null or E331Q expressing cells (Figure 12F). Consistent with an increased
frequency of catastrophe, growth events in TTL myocytes were shorter in
duration and traveled less distance, despite similar growth velocity (Figure 12G).
Of note, cells expressing E331Q showed comparable growth metrics and event
frequencies to control infected myocytes, indicating that TTL’s effect on
microtubule dynamics is due to tyrosination and not tubulin binding. Substantial
overexpression of TTL or E331Q could reduce growth velocity by limiting tubulin
available for polymerization; we calculated the predicted effect of our level of
overexpression on tubulin growth velocity and found a negligible effect on growth
kinetics (Figure 13D), consistent with our experimental observations (Figure
12G).
I next sought to provide an underlying mechanism for the tyrosinationdependent increase in catastrophe rate. I hypothesized that knockdown of MCAK
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in, a depolymerizing kinesin with preference for tyrosinated microtubules, in TTL
expressing myocytes would prevent the observed increase in catastrophe
frequency. To knockdown MCAK protein I purchased three short interfering
RNAs (siRNAs) specific for Kif2c, the RNA transcript for MCAK. To validate the
siRNAs I used the H9C2 rat cardiac myoblast cell line as these cells are
proliferative and should express more MCAK protein than adult myocytes. I also
used H9C2 cells to validate the commercially obtained antibody and qPCR
primers to quantify Kif2c expression. siRNAs for Kif2c were transfected into
H9C2s and allowed to express for 48 hours. Incubation of H9C2 lysate with the
antibody for MCAK resulted in a very faint band at the predicted molecular weight
(Figure 14A and B) suggesting quantification of MCAK protein knockdown with
the current antibody is unreliable. I selected siRNA #1 (siKif2c-1) to be made into
a short hairpin RNA (shRNA) and packaged into AAV. Expression of shRNA
specific for Kif2c in adult rat cardiomyocytes resulted in knockdown when
quantified by qPCR (Figure 14C); however, copy numbers of Kif2c in control
cells were high and close to the limit of detection suggesting expression of MCAK
is very low in the adult myocyte. Further validation is required to ensure that
MCAK is expressed in the adult rat cardiomyocyte and if MCAK knockdown is
successful before the stated hypothesis can be answered.
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A

B

C

Figure 14. Partial validation of MCAK knockdown. A Lysate from H9C2 cells transfected with
three siRNAs for Kif2c (MCAK transcript). Faint band at the predicted molecular weight was
quantified. B Quantification of H9C2 cells transfected with siRNA Kif2c-1from A. C Quantification
of Kif2c transcript by qPCR from adult rat cardiomyocytes transfected with shRNA for Kif2c.
Transcript was quantified by delta ct method compared to gapdh expression. For B N=3
independent plates of cells and C N=3 rats.

Desmin structures the growing microtubule network
We hypothesized that desmin intermediate filaments could be the Z-disc
stabilizing factor for growing microtubules, based in part on the gross microtubule
misalignment observed in the absence of desmin93, and from our observation
that microtubules tend to traverse the Z-disc at desmin-enriched regions46.
To determine if desmin regulates the dynamic population of microtubules, we
utilized the previously described fractionation assay (Figure 11B) with lysate
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from rat cardiomyocytes infected with adenoviruses encoding shRNA against
desmin (Des KD) or a scramble control (scram).

Figure 15. Desmin stabilizes the growing microtubule at the Z-disc. A Representative
western blot (left) and quantification (right) of α-tubulin, dTyr, acetylated tubulin, and GAPDH in
free, cold-sensitive, or whole-cell lysate from isolated rat cardiomyocytes expressing either
scramble (scrm) or desmin specific shRNA (Des KD). B Representative EB3-GFP kymograph
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from control or desmin KD myocytes. C Cell-wide catastrophe (left), rescue (middle), and pause
(right) frequency with or without desmin KD. D Number of catastrophes (left), pauses (middle),
and rescues (right) that occur on or off the Z-disc with or without desmin KD. E Frequency
distribution of average microtubule growth displacement, duration, and velocity with or without
desmin KD. F. Z-disc bias score (log2 transform of the ratio of events that occurred on vs. off the
Z-disk) for all experimental conditions. Data are normalized to the average control value for the
corresponding experiment. Statistical significance determined with Two Sample KolmogorovSmirnov Test. Data are presented as mean±SEM unless otherwise specified.

This construct has been previously validated to reduce desmin protein
levels ~70% under identical conditions6. Desmin depletion resulted in an
increased free to polymerized ratio in the dynamic microtubule pool (Figure 15A,
Figure 16A), suggesting that desmin coordinates the stability of dynamic
microtubules. We next quantified microtubule acetylation and detyrosination,
markers of long-lived microtubules, and found that both were decreased in
desmin depleted myocytes, without alterations in whole cell tubulin content
(Figure 15A).
We next directly quantified plus-end microtubule dynamics by EB3-GFP
upon desmin depletion. As seen in Movies 5-6 (in the appendix), upon desmin
depletion microtubule growth still initiated at the Z-disk, but the iterative,
longitudinal growth from one Z-disk to another seen in control cells was lost.
Instead, microtubules often grew past Z-disk regions without pausing (Figure
15B), and when breaking down they were less likely to be rescued at the
previous Z-disk. Blind quantification of global event frequency revealed that
desmin depletion modestly increased the frequency of catastrophes while more
robustly reducing both the frequency of rescues and pauses (Figure 15C).
Interrogation of where dynamic events occurred in relation to the Z-disk revealed
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that desmin depletion specifically increased the number of catastrophes that
occurred only on the Z-disk (Figure 15D), while reducing the number of
catastrophes that occurred off the Z-disk. More strikingly, desmin depletion
markedly reduced the number of pauses and rescues that occur specifically on
the Z-disk, while not affecting pause or rescue behavior elsewhere (Figure 15D).
Growth events tended to travel longer distance with higher velocities in Des KD
cells (Figure 15E). Together, these results indicate that desmin is spatially
coordinates microtubule dynamics and stabilizes both the growing and shrinking
microtubule at the Z-disk.
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Figure 16. Supporting data for figure 15. A Representative western blot (top) and
quantification (bottom) for ɑ-tubulin and GAPDH in free and cold-sensitive fractions from rat
cardiomyocytes infected with adenovirus containing scramble shRNA (scrm) or shRNA for
desmin (Des KD). B Representative electron microscopy images of isolated rat cardiomyocytes
with or without desmin knockdown. C Probability density plot of angle (top) and distance
(bottom) between adjacent Z-discs with or without desmin knockdown.
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As the Z-disk region coordinates microtubule dynamics, we sought to
summarize how our different interventions (TTL, Desmin KD) affected the spatial
organization of microtubule behavior. By taking the ratio of events that occurred
on vs. off the Z-disk and performing a log2 transform, we calculated a Z-disk bias
for each type of dynamic event (Figure 14F). Of note, this metric only reflects
the spatial bias of events, not their frequencies. TTL reduced the preference for
microtubule pausing at the Z-disk, but did not affect the spatial preference of
rescues, catastrophes, or initiations (TTL increased catastrophe frequency in a
spatially-agnostic fashion). Desmin depletion, on the other hand, virtually
eliminated any spatial preference of pausing, rescue, or catastrophe behavior.
Initiations had a strong Z-bias regardless of intervention, which likely reflects
nucleating events from microtubule organizing centers at Golgi outposts proximal
to the Z-disk that are not affected by these manipulations49.
Cardiomyocytes from global, desmin germ-line knockout mice are
characterized by misaligned and degenerated sarcomeres94 with a disorganized
microtubule network 32. Gross restructuring of the myofilaments could affect
microtubule dynamics due to a change in the physical environment that is
permissive to microtubule growth, for example by increasing the spacing
between Z-discs of adjacent myofilaments. To assess if our acute desmin
depletion altered myofilament spacing or alignment, we performed quantitative
measurements on electron micrographs from desmin depleted cardiomyocytes.
Blind analysis indicated that acute desmin depletion did not change myofilament
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spacing or alignment at this level of resolution (Figure 15B), consistent instead
with a direct stabilizing effect of desmin intermediate filaments on the microtubule
network.
We next wanted to visualize the effect of desmin depletion on whole-cell
microtubule network organization. Airyscan imaging and blind image
quantification indicated a reduction of the percent cell area occupied by both
detyrosinated and tyrosinated microtubules (Figure 17A-B), consistent with
reduced stability of microtubules upon desmin depletion. As a reduction in
detyrosinated microtubules and their association with the Z-disc is associated
with reduced cardiomyocyte viscoelasticity32, we hypothesized that desmindepleted myocytes would be less stiff. To test this, we performed transverse
nanoindentation of cardiomyocytes and quantified Young’s modulus of the
myocyte over a range of indentation rates. Desmin depletion specifically reduced
the rate-dependent (viscoelastic) stiffness of the myocyte (Figure 17C), without
significantly altering rate-independent (elastic) stiffness. Reduced viscoelasticity
is consistent with reduced transient interactions between dynamic cytoskeletal
filaments. To directly test if the reduction in desmin alters microtubule buckling
between sarcomeres, we performed a semi-automated, blind analysis of
microtubule buckling, as in our previous work32. In control cells, most
microtubules buckle in a clear sinusoidal pattern with a wavelength
corresponding to the distance of a contracted sarcomere (~1.5-1.9 µm) (Figure
17D and G, Movie 7). Upon desmin depletion, fewer polymerized microtubules
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were observed in general, with more chaotic deformations and organization upon
contraction Movie 8). For microtubules that did buckle, the amplitude of buckles
was reduced (Figure 17E), as well as the proportion of microtubules that buckled
at wavelengths corresponding to the distance between 1 or 2 sarcomeres (1.51.9 or 3.0-3.8 µm, respectively, Figure 17F). Combined, these results are
consistent with desmin coordinating the physical tethering and lateral
reinforcement of detyrosinated microtubules at the cardiomyocyte Z-disk to
regulate myocyte viscoelasticity.

71

Figure 17. Desmin facilitates the microtubule contribution to viscoelastic resistance. A.
Representative Airyscan images of desmin (magenta), detyrosinated tubulin (orange), and
tyrosinated tubulin (cyan) in isolated adult rat cardiomyocytes with or without desmin KD. B
Quantification of percent cell area coverage of detyrosinated microtubules and tyrosinated
microtubules with or without desmin KD. C Nanoindentation measurement of cardiomyocyte
viscoelasticity. Left, Stiffness (elastic modulus) as a function of probe indentation velocity with or
without desmin KD. Right, quantification of rate-dependent (viscoelastic) and independent
(elastic) stiffness. D Representative images of microtubules in a cardiomyocyte at rest (top) and
at the peak of contraction (bottom) with or without desmin KD. E Quantification of microtubule
buckle amplitude. F Left, histogram of wavelength distribution of individual microtubule buckles.
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Right, distribution difference (scram – des KD from G). Statistical significance determined via 2sided t test.

Discussion
In this paper we identify that 1) the dynamic, catastrophe-prone nature of
tyrosinated microtubules precludes their ability to faithfully grow to subsequent Zdiscs; and 2) desmin intermediate filaments structure and stabilize the growing
microtubule network.
This study represents the first direct observation that tyrosination
increases the dynamics of cardiac microtubules. Increased dynamicity seems
unlikely to arise from the PTM itself, 39 as the C-terminal tyrosine is not believed
to be critical involved in the formation of lateral contacts with other tubulin dimers
in the microtubule lattice. Yet, removal of this large hydrophobic residue and
subsequent exposure of acidic residues will alter hydrophobic and electrostatic
interactions on the outer surface of the polymerized microtubule. Through such a
mechanism, tyrosination can promote microtubule dynamics via increased
interaction with destabilizing MAPs, or through decreased interaction with
stabilizing MAPs 39,40.
For example, detyrosination reduces the affinity of the depolymerizing
kinesin MCAK for the microtubule, increasing microtubule stability55. We
hypothesized that increased MCAK affinity may contribute to the increased rate
of catastrophe we observed in tyrosinated microtubules; yet due to its low
73

abundance in the cardiomyocyte, our attempts to detect and knock down MCAK
levels were unreliable, precluding the immediate test of this hypothesis. The low
abundance of MCAK, while not ruling out a physiological rule, also motivates
interrogation into alternative stabilizing or destabilizing effector proteins.
We also identified that the intermediate filament desmin provides structure
to the growing microtubule network by stabilizing microtubules at the Z-disc.
What is the mechanism of desmin-dependent stabilization? A recent elegant in
vitro study using reconstituted vimentin intermediate filaments and microtubules
indicates that intermediate filaments are sufficient to stabilize growing
microtubules through electrostatic and hydrophobic interactions56. The interaction
with intermediate filaments reduces catastrophes and promotes rescues, in
strong accordance with our in cellulo findings here. While MAPs may also be
involved in modulating microtubule-intermediate filament interactions, this direct
effect is sufficient to explain the primary phenotypes observed upon desmin
depletion (i.e. increased catastrophes and reduced pausing in the absence of
desmin at the Z-disk, and a loss of Z-disk rescues).

The intermediate filament stabilization of growing microtubules would then
provide a longer-lived microtubule substrate to facilitate reinforcing,
detyrosination-dependent interactions, such as those previously documented
between desmin and the microtubule through intermediates such as Kinesin-158
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or members of the plakin family of scaffolding proteins57. Desmin-mediated
interaction along the length of the microtubule may also lead to the loss of tubulin
dimers at sites of contact; these lattice defects are replaced by GTP-tubulin,
which upon microtubule catastrophe may function as a rescue sites95. Lateral
interactions between microtubules and intermediate filaments govern microtubule
mechanical behavior upon compressive loading of microtubules85 allowing
desmin to orchestrate microtubule buckling in the cardiomyocyte. 34

Methods
Animals
Animal care and procedures were approved and performed in accordance
with the standards set forth by the University of Pennsylvania Institutional Animal
Care and Use Committee and the Guide for the Care and Use of Laboratory
Animals published by the US National institutes of Health.
Rat cardiomyocyte isolation and culture
Primary adult ventricular myocytes were isolated from 6- to 8-week-old
Sprague Dawley rats as previously described7. Briefly, rats were anesthetized
under isoflurane while the heart was removed and retrograde perfused on a
Lutgendorf apparatus with a collagenase solution. The digested heart was then
minced and triturated using a glass pipette. The resulting supernatant was
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separated and centrifuged at 300 revolutions per minute to isolate
cardiomyocytes that were resuspended in rat cardiomyocyte media at a density
that ensured adjacent cardiomyocytes did not touch. Cardiomyocytes were
cultured at 37°C and 5% CO2 with 25 μmol/L of cytochalasin D. The viability of
rat cardiomyocytes upon isolation was typically on the order of 50-75% rodshaped, electrically excitable cells, and the survivability for 48hrs of culture is
>80% (See Heffler et al. 6for our quantification of cardiomyocyte morphology in
culture).
Rat cardiomyocyte media: medium 199 (Thermo Fisher 115090) supplemented
with 1x Insulin-transferrin-selenium-X (Gibco 51500056), 1 μg μl-1 primocin
(Invivogen ant-pm-1), 20 mmol/L HEPES at pH 7.4 and 25 μmol/L cytochalasin
D.
Fractionation assay of free tubulin and cold-sensitive microtubules
Free tubulin was separated from cold-labile microtubules using a protocol
adapted from Tsutsui et al., 1993 and Ostlud et al., 1979. Isolated rat
cardiomyocytes were washed once with PBS and homogenized with 250 ul of
microtubule stabilizing buffer using a tissue homogenizer. The homogenate was
centrifuged at 100,000 xg for 15 minutes at 25°C and the resulting supernatant
was stored at -80°C as the free tubulin fraction. The pellet was resuspended in
ice-cold microtubule destabilizing buffer and incubated at 0°C for 1 hour. After
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centrifugation at 100,000 xg for 15 minutes at 4°C the supernatant containing the
cold-labile microtubule fraction was stored at -80°C.
Microtubule stabilizing buffer: 0.5 mM MgCl2, 0.5 mM EGTA, 10mM Na3PO4, 0.5
mM GTP, and 1X protease and phosphatase inhibitor cocktail (Cell Signaling
#5872S) at pH 6.95
Microtubule destabilizing buffer: 0.25 M sucrose, 0.5 mM MgCl2 10 mM Na3PO4,
0.5 mM GTP, and 1X protease and phosphatase inhibitor cocktail (Cell Signaling
#5872S) at pH 6.95
Western blot
For whole cell protein extraction, isolated rat cardiomyocytes were lysed in
RIPA buffer (Cayman #10010263) supplemented with protease and phosphatase
Inhibitor cocktail (Cell Signaling #5872S) on ice for 1 hour. The supernatant was
collected and combined with 4X loading dye (Li-COR #928-40004),
supplemented with 10% 2-mercaptoethonol, and boiled for 10 minutes. The
resulting lysate was resolved on SDS-PAGE gel and protein was blotted to
nitrocellulose membrane (Li-COR #926-31902) with mini Trans-Blot Cell (BioRad). Membranes were blocked for an hour in Odyssey Blocking Buffer (TBS)
(LI-COR #927-50000) and probed with corresponding primary antibodies
overnight at 4 °C. Membranes were rinsed with TBS containing 0.5% Tween 20
(TBST) three times and incubated with secondary antibodies TBS supplemented
with extra 0.2% Tween 20 for 1 hour at room temperature. Membranes were
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washed again with TBST (0.5% Tween 20) and imaged on an Odyssey Imager.
Image analysis was performed using Image Studio Lite software (LI-COR). All
samples were run in duplicates and analyzed in reference to GAPDH.
Antibodies and labels
Acetylated tubulin; mouse monoclonal (Sigma T6793-100UL); western blot: 1:
1,000
Detyrosinated tubulin; rabbit polyclonal (Abcam ab48389); western blot: 1: 1,000
Alpha tubulin; mouse monoclonal, clone DM1A (Cell Signaling #3873); western
blot: 1:1,000
Beta tubulin; rabbit polyclonal (Abcam ab6046); western blot: 1,000
Tyrosinated tubulin; mouse monoclonal (Sigma T9028-.2ML);
Immunofluorescence: 1:1000
Desmin; rabbit polyclonal (ThermoFisher PA5-16705); western blot and
immunofluorescence: 1: 1,000
GAPDH; mouse monoclonal (VWR GenScript A01622-40); western blot: 1:1,000
Goat anti-mouse AF 488 (1:1000 Life Technologies A11001)
Goat anti-rabbit AF 565 (1:1000 Life Technologies A11011)
IRDye 680RD Donkey anti-Mouse IgG (H + L) (LI-COR 926-68072); western blot:
1:10,000.
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IRDye 800CW Donkey anti-Rabbit IgG (H + L) (LI-COR 926-32213); western
blot: 1:10,000.

Microtubule Dynamics by EB3
Isolated rat cardiomyocytes were infected with an adenovirus containing
an EB3-GFP construct. After 48 hours, cells were imaged on an LSM Zeiss 880
inverted confocal microscope using a 40X oil 1.4 numerical aperture objective.
Cells expressing EB3-GFP only at the tip were imaged for four minutes at a rate
of 1fps. Files were blinded, Gaussian blurred, and Z-compressed using Image J
(National Institutes of Health) to generate kymographs. The number of
catastrophes, rescues, and pauses were recorded per kymograph in addition to
manual tracing of microtubule runs to quantify time, distance, and velocity of
microtubule growth or shrinkage. We refer to the entire kymograph as the
microtubule ‘track’ that is made up of individual growth and shrinkage events we
call ‘runs’. Catastrophe and rescue frequency were calculated per cell by dividing
the number of catastrophes or rescues by total time spent in growth or shrinkage
time, respectively. Catastrophes and rescues occurring specifically on or off the
Z-disc were normalized by the total time of microtubule growth and shrinkage.
Experimental values were normalized to their respective control cells (Null for
TTL and E331Q, or shScrm for shDes) acquired from the same animals. A
minimum of 3 separate cell isolations were performed for each group.
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Immunofluorescence
Cells were fixed in pre-chilled 100% methanol for 8 minutes at -20°C.
Cells were washed 4x then blocked with Sea Block Blocking Buffer (abcam
#166951) for at least 1 hour followed by antibody incubation for 24-48 hours.
Incubation was followed by washing 3x with Sea Block, then incubated with
secondary antibody for 1 hour. Fixed cells were mounted using Prolong Diamond
(Thermo #P36961)
We used ImageJ to calculate the percent area fraction of both desmin and
microtubules. An ROI was drawn to include the entire cell boundary minus the
nucleus. For each image we identified the percent fractional coverage of a
fluorescence signal over a manually identified threshold as described
previously46.
Buckling analysis

Adult rat cardiomyocytes were isolated as previously described and
infected with adenovirus carrying the microtubule-binding protein EMTB
chimerically fused to 3 copies of GFP. The purpose of this construct was to label
microtubules fluorescently for imaging. The cells were allowed 48 hours to
express the construct. All cells chosen were those that contained sufficient
brightness and contrast to observe microtubule elements and where the health of
the myocyte was not compromised. To interrogate microtubule buckling
amplitude and wavelength, cells were induced to contract at 1 Hz 25 V and
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imaged during the contraction. For analysis, images were blinded, and a
microtubule was located that could be followed during the contraction. The
backbone was manually traced at rest and during its peak of contraction and the
ROI was saved. The ROI was then analyzed using a macro that rotated so that
the ROI had the peak of contraction 90 degrees to the axis of contraction to
protect from aliasing errors. The program then calculated the distance between
the axis of the ROI and its peak and calculated the peak (amplitude) and the
width (half wavelength).
Electron Microscopy
Transmission electron microscopy images were collected as previously
described 6. Images at 7500x were rotated so the cells were parallel to the
longitudinal axis. ROIs were generated between adjacent Z-discs to quantify
sarcomere spacing and the angle relative to 90°.
Statistics
Statistical analysis was performed using OriginPro (Version 2018).
Normality was determined by Shapiro-Wilk test. For normally distributed data,
two sample t-test or one-way ANOVA was utilized as appropriate. For nonnormally distributed data, two sample Kolmogrov-Smirnov test or Kruskal-Wallis
ANOVA was utilized as appropriate. Specific statistical tests and information of
biological and technical replicates can be found in the figure legends. Unless
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otherwise noted, ‘N’ indicates the number of cells analyzed and ‘n’ indicates
number of microtubule runs.
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS
Adapted from:
Chen, C. Y*., Salomon, A. K*., Caporizzo, M. A., Curry, S., Kelly, N. A., Bedi, K.,
… & Prosser, B. L. (2020). Depletion of vasohibin 1 speeds contraction and
relaxation in failing human cardiomyocytes. Circulation research, 127(2), e14e27.
Manuscript currently in review at eLife: Salomon A.K., Okami N., Heffler, J., Lee
JJ., Robison P., Bogush AI., Prosser BL. (2021). Desmin intermediate filaments
and tubulin detyrosination stabilize growing microtubules in the cardiomyocyte.

In this dissertation I define the mechanical role of the cardiac microtubule
network and begin to shed light on how the network is formed. Specifically, I find
that: 1) Depolymerization of the microtubule network improves contractility of
cardiomyocytes isolated from failing human hearts; 2) The VASH-SVBP complex
functions as a tubulin carboxypeptidase in cardiomyocytes and knockdown
improves contractility of failing human cardiomyocytes; 3) The dynamic,
catastrophe-prone nature of tyrosinated microtubules precludes their ability to
faithfully grow between subsequent Z-discs; and 4) Desmin intermediate
filaments provide structure to and stabilize dynamic microtubules.
Although the cardiomyocyte microtubule network is necessary for the
function of the myocyte, its presence contributes viscoelastic resistance to
myocyte motion. In the healthy myocyte, the resistive force provided by
microtubules buckling at a short wavelength is thought to equal 5-40% of the total
force generated by the myocyte.32 While this resistance is negligible for the
healthy myocyte as contraction is obviously not stalled, the densification of the
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microtubule network that occurs in heart disease is sufficient to depress myocyte
contractility. Why might the microtubule network increase in density during
disease if its presence hinders contractility? In disease ventricular pressure can
change, potentiating an increase in wall stress felt by the myocardium.
Microtubules are known to be stabilized under tension and align with the direction
of maximal tensile stress in plant cells96. Cardiomyocyte microtubules may
function in a similar way. By sensing changes in the direction and magnitude of
tensile stress, the microtubule network may reactively coordinate changes in
myocyte geometry. For example, increased microtubule polymerization and
stability in one axis may bias the localization of transcripts necessary for the
formation of the sarcomere, allowing the cell to change shape so that it may
compensate for the change in ventricular pressure. 9,97
The viscoelastic resistance provided by the microtubule network is tuned
by detyrosination. Expression of TTL or knockdown of VASH1-SVBP specifically
resulted in increased myocyte relaxation velocity. Diastolic dysfunction, or slowed
myocyte relaxation, is a hallmark of both hypertrophic cardiomyopathy (HCM)
and heart failure with preserved ejection fraction (HFpEF).4,62 Reducing
cardiomyocyte stiffness and improving myocyte relaxation may reduce relaxation
times, increase ventricular compliance, and reduce diastolic pressures, all of
which may benefit patients with diastolic dysfunction. As there is no cure for HCM
or HFpEF, current disease management is focused on preventing thrombotic
events and sudden cardiac death either through pharmacological therapies or
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surgical intervention (Solomon 2020). Therefore, pharmacological approaches to
promote myocyte relaxation to treat HCM represent an unmet clinical need.
Current pharmacological approaches in development including calcium
desensitizers98,99, genome editing with CRISPR100, and most notably
mavacamten, a myosin inhibitor in clinical trials.101 It is unclear if the therapeutic
benefit of such approaches arises from the faster relaxation, reduced systolic
force production, or a net decrease in time under tension that may limit
hypertrophic remodeling. Intriguingly, our results indicate an alternative, Ca2+independent mechanism to speed relaxation. Reducing viscoelasticity may speed
cardiomyocyte relaxation without compromising systolic force production or
increasing energetic demand, as would be the case for an increase in calcium
cycling. How such a strategy would fit in the toolkit and compare to current
approaches for treating different etiologies of diastolic or systolic dysfunction is of
interest and will require extensive further study.
The differences between the enzymatic activity and expression of VASH1
and VASH2 in cardiomyocytes warrant further study. The catalytic activity of the
vasohibins is contingent on interaction with SVBP, which maintains the structural
integrity of the VASH active site.70,71 Interestingly, SVBP transcript is more
abundant in cardiac tissue than either isoform of VASH, suggesting regulation of
the individual isoforms may reside in their individual transcription or posttranslational modification. While VASH1 transcript is more abundant in cardiac
tissue, VASH2 knockdown also resulted in reduced levels of microtubule
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detyrosination. While we cannot determine the differences in enzyme kinetics
between the two VASH isoforms from our data, it is possible that VASH2 may be
expressed at a lower level but have an increased microtubule affinity compared
to VASH1. Further, the effect of VASH2 knockdown on the contractility of
cardiomyocytes from diseased hearts was not investigated. Future studies
should characterize the expression of VASH2 in diseased cardiomyocytes and
explore its role in mediating increased levels of detyrosination observed in
disease.
This dissertation also represents the first direct observation that
tyrosination increases the dynamics of cardiac microtubules. What is the
mechanism underlying the effect of tyrosination on microtubule dynamics? As
discussed previously, tyrosination likely alters the interaction of plus-end tip
proteins (+Tips), such as CLIP-170 and p150 glued92, which may tune
microtubule dynamics through either direct or indirect effects. +Tip proteins also
serve to couple the growing microtubule plus end with cellular effectors29. In the
search and capture mechanism, dynamic microtubules ‘search’ for sites on the
plasma membrane, chromosomes, and organelles to ‘capture’ via +Tip
proteins.102 The interaction of microtubules with cellular structures, such as
chromosomes or the cell cortex, has been shown to promote rescue events
through the formation of tension at the plus-end.103
Further study is required on the expression, activity, and regulation of +Tip
proteins in both the healthy and diseased cardiomyocyte. Regulation of
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microtubule dynamics is likely a critical intermediate in the formation of the dense
microtubule network observed in disease. Much of what is known about the
regulation of +Tip proteins comes from mitotic cells, were a milieu of microtubule
associated proteins, regulatory proteins, and kinases is involved in maintaining
proper spindle position and length to ensure proper cell division.104 Preliminary
investigation into the expression of MCAK, a key depolymerizing kinesin that
preferentially interacts with tyrosinated microtubules, suggested that expression
is very low to non-detectable in the cardiomyocyte. This is in agreement with
other reports that suggest MCAK is expressed in proliferating skeletal myoblasts
but downregulated to undetectable levels in differentiated mouse skeletal
muscle.105 Other depolymerizing kinesins such as Kif15 and Kif2a may act
preferentially in the cardiomyocyte, and their expression and activity should be
explored.106 Further, dynamic microtubules are required for the differentiation of
myoblasts.107 An intriguing hypothesis then arises that any changes to
microtubule dynamics in disease progression due to changes in the expression
and regulation of +Tip proteins may be linked to the fetal reprogramming and
dedifferentiation that occurs during heart disease.108
I found that microtubule acetylation does not impact microtubule
dynamics; however, this result should be contextualized. Acetylation of the
polymerized microtubule is known to occur rather slowly as aTAT1 has a slow
catalytic rate (0.4 hr-1).109 Further, the lysine residue that serves as a substrate
for aTAT1 is in the lumen of the microtubule, thus the enzyme must enter the
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lumen though the microtubule ends or via lattice defects that accumulate through
damage of the microtubule.109 Although the expression of the aTAT1 construct in
my experiments robustly increased acetylation, the pattern of acetylation likely
differs from what would accumulate endogenously through cyclic strain of the
microtubule. The accumulation of acetylation at points of high microtubule
curvature may allow for increased resistance to catastrophe, allowing for selfrepair of damaged microtubules with GTP tubulin.95 The formation of these
rescue sites (called GTP islands110) would likely have a subtle effect on the
overall dynamics of the microtubule that would likely be missed by the cellfractionation assay used to determine the effect of acetylation of microtubule
dynamics. Further study on the effects of acetylation on microtubule dynamics is
warranted and should include cyclic electrical stimulation to produce microtubule
defects.
The intermediate filament desmin was also found to provide structure to
the growing microtubule network by stabilizing microtubules at the Z-disc. What
is the mechanism of desmin-dependent stabilization? A recent elegant in vitro
study using reconstituted vimentin intermediate filaments and microtubules
indicates that intermediate filaments are sufficient to stabilize growing
microtubules through electrostatic and hydrophobic interaction56. The interaction
with intermediate filaments reduces catastrophes and promotes rescues, in
strong accordance with my in cellulo findings. While MAPs may also be involved
in modulating microtubule-intermediate filament interactions, this direct effect is
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sufficient to explain the primary phenotypes observed upon desmin depletion (i.e.
increased catastrophes and reduced pausing in the absence of desmin at the Zdisk, and a loss of Z-disk rescues).
The intermediate filament stabilization of the growing microtubule would
subsequently allow for more durable interactions between intermediate filaments
and the microtubule, contributing to the long-range stability of the network. For
example, microtubules are known to be cross-linked with intermediate filaments
via Kinesin-158 or members of the plakin family of scaffolding proteins.57 Through
interaction with microtubules, intermediate filaments have been shown to inhibit
microtubule dynamics, contributing to microtubule stability in motor neurons.111
Additionally, the formation of extensive cross-links between desmin intermediate
filaments and the microtubule network, likely increases the steric hinderance of
tubulin associated with microtubules at the Z-disc. An interesting possibility
arises that molecular crowding further reinforces microtubule stability observed
by desmin intermediate filaments.
Combined with past and current work, I propose a unifying model for
microtubule-intermediate filament interactions in the cardiomyocyte and how they
contribute to myocardial mechanics (Figure 17) . Detyrosinated microtubules,
with less frequent depolymerization, experience more chance interactions with
intermediate filaments at the Z-disc. The altered surface chemistry of
detyrosinated microtubules may also strengthen the electrostatic interactions with
intermediate filaments and additional cross-linking proteins. The periodic, lateral
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reinforcement of microtubules increases their stability, leading to longer-lived
microtubules and providing a dynamic cross-link with the sarcomere, increasing
the viscoelastic resistance to myocyte motion and the ability of microtubules to
transduce mechanical stress. Increased microtubule lifetimes also promote
microtubule acetylation, which itself increases the ability of microtubules to
withstand mechanical stress54 and increases myocyte viscoelasticity.112 In the
setting of heart disease, the increased abundance of both desmin intermediate
filaments and detyrosinated microtubules thus promotes a feed-forward substrate
for enhanced mechanotransduction and myocardial stiffening.

Figure 17. Current working model for how the microtubule network is shaped by
tyrosination status and desmin intermediate filaments.
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184
357

251

241

283
200
217
187
277
138
418
240

272
170
215
187
184
152

Patient # Etiology Gender Age (year) Heart Weight (g)

122.26

160.69
187.51
130.81
128.38
171.88

111.33

106.89

132.06
112.87
115.19
102.32
138.61
78.75
152.28
111.48

140.43
91.52
106.18
102.42
76.87
88.75

LVMI

60

65
75
60
70
75

20

10

15
25
15
15
15
20
25
20

75
50
60
40
55
70

LVEF (%)

AFM; VASH1 KD v Scram Ca2+ and Contractility; SVBP KD v Scram Contractility

TTL v Null contractility Ca2+ and contractility
VASH1 KD v Scram Contractility
VASH1 KD v Scram Contractility
VASH1 KD v Scram Contractility
AFM; VASH1 KD v Scram Ca2+ and Contractility

AFM; SVBP KD v Scram Contractility

VASH1 KD v Scram Ca2+ and Contractility; SVBP KD v Scram Contractility

TTL v Null Ca2+ and contractility
TTL v Null Ca2+ and contractility
TTL/E331Q/Null contractility
TTL/E331Q/Null contractility
TTL/E331Q/Null contractility, VASH1 KD v Scram Contractility
VASH1 KD v Scram Contractility
VASH1 KD v Scram Contractility
AFM

TTL/E331Q/Null contractility
VASH1KD v Scram Contractility
TTL/E331Q/Null contractility; VASH1 KD v Scram Contractility
TTL/E331Q/Null contractility; VASH1 KD v Scram Contractility
VASH1 KD v Scram Ca2+ and Contractility
VASH1 KD v Scram Ca2+ and Contractility

Experiments on cultured cells

Online Table I. Descriptive statistics on human hearts in functional studies. A summary and detailed values for the human hearts used in this
study, including etiology, gender, age, heart weight, left ventricle mass index (LVMI) and left ventricular ejection fraction (LEVF) and experiments
performed on isolated myocytes.

APPENDIX

Appendix Table 1. Descriptive statistics on human hearts in Chapter 3. A summary and
detailed values for the human hearts used in this study, including etiology, gender, age, heart

weight, left ventricle mass index (LVMI) and left ventricular ejection fraction (LEVF) and
experiments performed on isolated myocytes.

Appendix Figure 1. Validation of antibodies against VASH1. HEK293T cells were used to
validate VASH1 antibodies as they do not endogenously express vasohibins. Immunoblots of
protein extracts from (A) HEK293T cells co-transfected with plasmids encoding mouse VASH1 and
mouse or human SVBP-myc-Flag (plasmids used in Aillaud et al Science 2017,48 Wang et al
201970). The VASH1 antibody made in Grenoble (Gre) detects a robust band with low antibody
concentration (1/20,000) only in the VASH1 overexpressing cells, while the VASH1 antibody from
Abcam detects a weaker signal at higher concentrations (1/1,000) in all conditions and is insensitive
to overexpression, indicating non-specificity. B, human LV myocardium blotted with anti-VASH1
antibodies. Gre antibody detects multiple weak bands around the predicted molecular weight of
VASH1, while Abcam antibody detects an extremely robust, albeit likely non-specific band (due to
non-specificity shown in A and C). C, immunoblots of protein extracts from rat myocytes: left, whole
cell extract and co-IP with anti-SVBP (Gre) blotted with anti-VASH1 (Gre); right, whole cell extract
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blotted with anti-VASH1 (Abcam). The Gre antibody reveals multiple bands in whole cell lysate,
and upon co-IP with anti-SVBP bands around the molecular weight of VASH1 are detected, but are
present even in negative control lanes (scram and scram + rabbit IgG). In sum, we were unable to
reliably quantify VASH1 in rat cardiomyocytes or human tissue. Validation was completed by
Christina Chen.
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Etiology
NF
NF
HFrEF
HFrEF
HFpEF
HFpEF

Figure 3B-D VASH KD contractility

Etiology
NF
NF
HF
HF
Etiology
NF
NF
HF
HF

Etiology
HF
HF

Figure 4B VASH KD calcium

Figure 4C VASH KD contractility

Online Figure 2 SVBP KD contractility

Etiology
NF
NF
NF
HF
HF
HF

Etiology
HF
HF

Figure 1B TTL Calcium

Figure 3C-D TTL/TTL-E331Q
contractility

Etiology
HF
HF

Figure 1B TTL contractility

N (patients)
3
3

N (patients)
2
2
3
3

N (patients)
2
2
3
3

N (patients)
3
3
3
3
3
3

N (patients)
3
3
3
3
3
3

N (patients)
3
3

N (patients)
3
3

Treatment
Scram
SVBP KD

Treatment
Scram
VASH KD
Scram
VASH KD

Treatment
Scram
VASH KD
Scram
VASH KD

Treatment
Null
TTL
TTL-E331Q
Null
TTL
TTL-E331Q

Treatment
Scram
VASH KD
Scram
VASH KD
Scram
VASH KD

Treatment
Null
TTL

Treatment
Null
TTL

n (cells)
79
81

n (cells)
66
67
67
75

n (cells)
66
67
67
75

n (cells)
70
71
72
60
60
61

n (cells)
87
86
71
75
72
78

n (cells)
46
50

n (cells)
65
70

Resting SL (μm)
1.75 ± 0.01
1.71 ± 0.012

Resting SL (μm)
1.66 ± 0.013
1.71 ± 0.013
1.7 ± 0.013
1.7 ± 0.013

F0
69.22 ± 3.67
53 ± 3.7
82.72 ± 5.82
61.29 ± 3.19

Resting SL (μm)
1.84 ± 0.008
1.85 ± 0.009
1.85 ± 0.007
1.82 ± 0.01
1.84 ± 0.01
1.84 ± 0.012

Resting SL (μm)
1.79 ± 0.008
1.81 ± 0.006
1.8 ± 0.012
1.8 ± 0.01
1.78 ± 0.013
1.78 ± 0.012

Rise time 90% (s)
0.05 ± 0.004
0.05 ± 0.003

Resting SL (μm)
1.69 ± 0.011
1.73 ± 0.011

Peak ontraction velocity (μm/s)
-0.6 ± 0.055
-0.83 ± 0.073

Peak ontraction velocity (μm/s)
-0.44 ± 0.025
-0.64 ± 0.037
-0.36 ± 0.035
-0.5 ± 0.038

F/F0
3.24 ± 0.19
3.99 ± 0.33
2.97 ± 0.23
3.09 ± 0.15

Peak ontraction velocity (μm/s)
-1.06 ± 0.072
-1.49 ± 0.098
-1.54 ± 0.107
-0.59 ± 0.049
-0.81 ± 0.056
-0.78 ± 0.064

Peak ontraction velocity (μm/s)
-1.45 ± 0.067
-1.91 ± 0.081
-0.54 ± 0.05
-0.91 ± 0.075
-0.53 ± 0.055
-0.85 ± 0.064

Decay time 90 (s)
0.99 ± 0.029
1.03 ± 0.032

Peak ontraction velocity (μm/s)
-0.61 ± 0.037
-0.91 ± 0.048

Peak shortening (μm)
0.16 ± 0.009
0.17 ± 0.01

Peak shortening (μm)
0.12 ± 0.006
0.15 ± 0.007
0.11 ± 0.008
0.13 ± 0.008

Rise time 50% (s)
0.025 ± 0.001
0.027 ± 0.002
0.034 ± 0.003
0.036 ± 0.003

Peak shortening (μm)
0.16 ± 0.007
0.19 ± 0.008
0.19 ± 0.008
0.12 ± 0.007
0.14 ± 0.008
0.13 ± 0.007

Peak shortening (μm)
0.21 ± 0.005
0.23 ± 0.005
0.13 ± 0.008
0.17 ± 0.009
0.12 ± 0.009
0.17 ± 0.008

Decay time 25% (s)
0.69 ± 0.024
0.73 ± 0.028

Peak shortening (μm)
0.14 ± 0.009
0.17 ± 0.008

Online Table II. Statistical parameters of contractility and calcium transients of those presented in Fig 1, Fig 3 and Fig 4. Contractility and calcium transient
measurements are shown as mean ± SEM, with number of myocytes and hearts studied in each group.

Fractional shortening (%)
8.93 ± 0.497
10.11 ± 0.59

Fractional shortening (%)
7.19 ± 0.381
9.03 ± 0.426
6.27 ± 0.484
7.97 ± 0.482

Rise time 90% (s)
0.071 ± 0.003
0.072 ± 0.005
0.081 ± 0.005
0.089 ± 0.006

Fractional shortening (%)
8.83 ± 0.396
10.22 ± 0.467
10.51 ± 0.473
6.41 ± 0.397
7.58 ± 0.44
7.1 ± 0.404

Fractional shortening (%)
11.97 ± 0.273
12.87 ± 0.3
7.21 ± 0.474
9.48 ± 0.512
6.83 ± 0.483
9.47 ± 0.419

Decay time 50% (s)
0.37 ± 0.012
0.36 ± 0.011

Fractional shortening (%)
8.42 ± 0.518
9.68 ± 0.471

Peak relaxation velocity (μm/s)
0.7 ± 0.08
1 ± 0.116

Peak relaxation velocity (μm/s)
0.47 ± 0.039
0.76 ± 0.053
0.33 ± 0.039
0.58 ± 0.06

Decay time 50% (s)
0.611 ± 0.023
0.604 ± 0.023
0.603 ± 0.022
0.561 ± 0.018

Peak relaxation velocity (μm/s)
1.63 ± 0.125
1.9 ± 0.115
2.03 ± 0.171
0.7 ± 0.079
1.2 ± 0.127
0.78 ± 0.092

Peak relaxation velocity (μm/s)
1.51 ± 0.056
1.79 ± 0.062
0.71 ± 0.083
1.12 ± 0.099
0.41 ± 0.041
0.81 ± 0.065

F/F0
3.03 ± 0.146
2.84 ± 0.112

Peak relaxation velocity (μm/s)
0.81 ± 0.081
1.24 ± 0.088

Time to peak 50% (s)
0.19 ± 0.007
0.17 ± 0.005

Time to peak 50% (s)
0.2 ± 0.007
0.17 ± 0.004
0.25 ± 0.012
0.2 ± 0.007

Decay time 90% (s)
1.197 ± 0.029
1.179 ± 0.032
1.2 ± 0.034
1.126 ± 0.031

Time to peak 50% (s)
0.13 ± 0.005
0.11 ± 0.004
0.11 ± 0.004
0.19 ± 0.01
0.15 ± 0.008
0.17 ± 0.008

Time to peak 50% (s)
0.11 ± 0.003
0.1 ± 0.002
0.18 ± 0.008
0.15 ± 0.007
0.23 ± 0.014
0.18 ± 0.01

Time to peak 50% (s)
0.18 ± 0.007
0.13 ± 0.004

Ti

Ti

Deca

Ti

Ti

Ti

Peak ontraction velocity (μm/s)
-0.44 ± 0.025
-0.64 ± 0.037
-0.36 ± 0.035
-0.5 ± 0.038

Peak ontraction velocity (μm/s)
-0.6 ± 0.055
-0.83 ± 0.073

μm)
13
13
3
3

μm)
1
12

82
19

F/F0
3.24 ± 0.19
3.99 ± 0.33
2.97 ± 0.23
3.09 ± 0.15

Peak shortening (μm)
0.16 ± 0.009
0.17 ± 0.01

Peak shortening (μm)
0.12 ± 0.006
0.15 ± 0.007
0.11 ± 0.008
0.13 ± 0.008

Rise time 50% (s)
0.025 ± 0.001
0.027 ± 0.002
0.034 ± 0.003
0.036 ± 0.003

Fractional shortening (%)
8.93 ± 0.497
10.11 ± 0.59

Fractional shortening (%)
7.19 ± 0.381
9.03 ± 0.426
6.27 ± 0.484
7.97 ± 0.482

Rise time 90% (s)
0.071 ± 0.003
0.072 ± 0.005
0.081 ± 0.005
0.089 ± 0.006
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67

Fractional shortening (%)
8.83 ± 0.396
10.22 ± 0.467
10.51 ± 0.473
6.41 ± 0.397
7.58 ± 0.44
7.1 ± 0.404

Peak shortening (μm)
0.16 ± 0.007
0.19 ± 0.008
0.19 ± 0.008
0.12 ± 0.007
0.14 ± 0.008
0.13 ± 0.007

Peak ontraction velocity (μm/s)
-1.06 ± 0.072
-1.49 ± 0.098
-1.54 ± 0.107
-0.59 ± 0.049
-0.81 ± 0.056
-0.78 ± 0.064

μm)
08
09
07
1
1
12

Fractional shortening (%)
11.97 ± 0.273
12.87 ± 0.3
7.21 ± 0.474
9.48 ± 0.512
6.83 ± 0.483
9.47 ± 0.419

Peak shortening (μm)
0.21 ± 0.005
0.23 ± 0.005
0.13 ± 0.008
0.17 ± 0.009
0.12 ± 0.009
0.17 ± 0.008

Peak ontraction velocity (μm/s)
-1.45 ± 0.067
-1.91 ± 0.081
-0.54 ± 0.05
-0.91 ± 0.075
-0.53 ± 0.055
-0.85 ± 0.064

μm)
08
06
2
1
13
12

Decay time 50% (s)
0.37 ± 0.012
0.36 ± 0.011

Decay time 25% (s)
0.69 ± 0.024
0.73 ± 0.028

Decay time 90 (s)
0.99 ± 0.029
1.03 ± 0.032

(s)
04
03

Fractional shortening (%)
8.42 ± 0.518
9.68 ± 0.471

Peak shortening (μm)
0.14 ± 0.009
0.17 ± 0.008

Peak ontraction velocity (μm/s)
-0.61 ± 0.037
-0.91 ± 0.048

μm)
11
11

Fig 3 and Fig 4. Contractility and calcium transient

Appendix Table 2. Statistical parameters of contractility and calcium transients of those
presented in Chapter 3. Contractility and calcium transient measurements are shown as mean
± SEM, with number of myocytes and hearts studied in each group.
Peak relaxation velocity (μm/s)

± 0.08
Online0.7
Figure
2
1 ± 0.116
SVBP KD
Contractility

Figure 4C VASH
KD Calcium

Peak relaxation velocity (μm/s)
0.47 ± 0.039
0.76 ± 0.053
0.33 ± 0.039
0.58 ± 0.06

0.561 ± 0.018

Decay time 50% (s)

Figure
VASH
0.6114B
± 0.023
0.604 ± 0.023
KD Calcium
0.603 ± 0.022

0.78 ± 0.092

Peak relaxation velocity (μm/s)
Figure
3C-D
1.63 ± 0.125
1.9 ± 0.115
TTL/TTL-E331Q
2.03 ± 0.171
0.7 ± 0.079
Contractility
1.2 ± 0.127

0.41 ± 0.041
0.81 ± 0.065

Peak relaxation
velocity (μm/s)
Figure
3B-D
1.51 ± 0.056
± 0.062
VASH1.79KD
0.71 ± 0.083
Contractility
1.12 ± 0.099

F/F0
3.03 ± 0.146
2.84 ± 0.112

Peak relaxation
Figure
1Bvelocity
TTL(μm/s)
0.81 ± 0.081
Contractility
1.24 ± 0.088

Time to peak 50% (s)
0.19 ± 0.007
0.17 ± 0.005

Time to peak 50% (s)
0.2 ± 0.007
0.17 ± 0.004
0.25 ± 0.012
0.2 ± 0.007

Decay time 90% (s)
1.197 ± 0.029
1.179 ± 0.032
1.2 ± 0.034
1.126 ± 0.031

Time to peak 50% (s)
0.13 ± 0.005
0.11 ± 0.004
0.11 ± 0.004
0.19 ± 0.01
0.15 ± 0.008
0.17 ± 0.008

Time to peak 50% (s)
0.11 ± 0.003
0.1 ± 0.002
0.18 ± 0.008
0.15 ± 0.007
0.23 ± 0.014
0.18 ± 0.01

Time to peak 50% (s)
0.18 ± 0.007
0.13 ± 0.004

Time to peak 90% (s)
0.47 ± 0.014
0.42 ± 0.01

Time to peak 90% (s)
0.48 ± 0.014
0.46 ± 0.011
0.55 ± 0.016
0.48 ± 0.012

Decay exponential fit (tau)
0.94 ± 0.05
0.89 ± 0.05
0.94 ± 0.05
0.8 ± 0.04

Time to peak 90% (s)
0.31 ± 0.009
0.27 ± 0.009
0.27 ± 0.007
0.39 ± 0.016
0.33 ± 0.011
0.35 ± 0.013

Time to peak 90% (s)
0.3 ± 0.006
0.26 ± 0.005
0.42 ± 0.012
0.37 ± 0.012
0.51 ± 0.022
0.42 ± 0.016

Time to peak 90% (s)
0.48 ± 0.033
0.24 ± 0.011

Time to relax 50% (s)
0.41 ± 0.015
0.34 ± 0.013

Time to relax 50% (s)
0.37 ± 0.012
0.31 ± 0.011
0.5 ± 0.015
0.38 ± 0.015

Time to relax 50% (s)
0.2 ± 0.009
0.16 ± 0.006
0.18 ± 0.009
0.29 ± 0.017
0.21 ± 0.01
0.23 ± 0.01

Time to relax 50% (s)
0.18 ± 0.006
0.16 ± 0.006
0.31 ± 0.013
0.23 ± 0.009
0.48 ± 0.019
0.34 ± 0.019

Time to relax 50% (s)
0.38 ± 0.019
0.24 ± 0.008

Time to relax 90% (s)
0.63 ± 0.022
0.56 ± 0.02

Time to relax 90% (s)
0.6 ± 0.019
0.5 ± 0.02
0.79 ± 0.025
0.64 ± 0.023

Time to relax 90% (s)
0.37 ± 0.022
0.3 ± 0.016
0.36 ± 0.022
0.61 ± 0.029
0.44 ± 0.028
0.57 ± 0.031

Time to relax 90% (s)
0.34 ± 0.018
0.31 ± 0.017
0.55 ± 0.027
0.44 ± 0.024
0.72 ± 0.022
0.58 ± 0.027

Time to relax 90% (s)
0.59 ± 0.024
0.46 ± 0.023

Relaxation exponential fit (tau)
0.58 ± 0.03
0.44 ± 0.027

Relaxation exponential fit (tau)
0.48 ± 0.028
0.37 ± 0.023
0.7 ± 0.029
0.52 ± 0.03

Relaxation exponential fit (tau)
0.2 ± 0.016
0.14 ± 0.007
0.19 ± 0.012
0.34 ± 0.03
0.23 ± 0.017
0.26 ± 0.015

Relaxation exponential fit (tau)
0.17 ± 0.008
0.15 ± 0.009
0.39 ± 0.032
0.24 ± 0.017
0.66 ± 0.034
0.43 ± 0.034

Relaxation exponential fit (tau)
0.44 ± 0.014
0.33 ± 0.01

Online Table III. Detailed two-way ANOVA report of human cardiomyocyte contractility kinetic data shown Figure 3C.
Overall ANOVA and mean comparisons including interactions from two-way ANOVA of contraction time and relaxation time
in VASH1KD and TTL/E331Q overexpression experiments are listed.

VASH1KD contraction time (90%) two way ANOVA
Overall ANOVA
DF
Etiology
Treatment
Interaction
Model
Error
Corrected Total

2
1
2
5
463
468

Mean comparison
Etiology
Prob
HFrEF NF
HFpEF NF
HFpEF HFrEF

1.57E-16
5.03E-39
2.09E-07

Treatment
Prob
shVASH scram

4.93E-08

Interaction
Etiology
NF
HFrEF
HFrEF
HFrEF
HFrEF
HFrEF
HFpEF
HFpEF
HFpEF
HFpEF
HFpEF
HFpEF
HFpEF
HFpEF
HFpEF

Sum of Squares Mean Square
F Value
P Value
2.75809
1.37904
109.85259
0
0.44096
0.44096
35.12647
6.04E-09
0.0733
0.03665
2.91943
0.05496
3.20211
0.64042
51.01505
0
5.81231
0.01255 --9.01442 ---Alpha

Sig
0.05
0.05
0.05

Alpha

Treatment
shVASH
scram
scram
shVASH
shVASH
shVASH
scram
scram
scram
scram
shVASH
shVASH
shVASH
shVASH
shVASH

1
1
1
Sig

0.05
Etiology
NF
NF
NF
NF
NF
HFrEF
NF
NF
HFrEF
HFrEF
NF
NF
HFrEF
HFrEF
HFpEF

1
Treatment
scram
scram
shVASH
scram
shVASH
scram
scram
shVASH
scram
shVASH
scram
shVASH
scram
shVASH
scram

Prob

Alpha
0.4535
1.93E-09
1.57E-15
0.00301
1.56E-07
0.08284
1.60E-27
5.71E-36
9.52E-06
2.71E-13
1.02E-09
4.90E-16
1
0.08226
3.81E-06

0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05

TTL/E331Q contraction time (90%) two way ANOVA
Overall ANOVA
DF

Sum of Squares Mean Square
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F Value

P Value

TTL/E331Q contraction time (90%) two way ANOVA
Overall ANOVA
DF
Etiology
Treatment
Interaction
Model
Error
Corrected Total

1
2
2
5
388
393

Mean comparison
Etiology
Prob
HF NF

1.23E-15

Treatment
Null E331Q
TTL E331Q
TTL Null

0.00341
0.50226
1.42E-05

Interaction
Etiology
NF
NF
NF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF

Sum of Squares Mean Square
F Value
P Value
0.53821
0.53821
69.45514
1.37E-15
0.1782
0.0891
11.49798
1.41E-05
0.00749
0.00374
0.48311
0.61723
0.72188
0.14438
18.63151
1.34E-16
3.00664
0.00775 --3.72852 ---Alpha

Prob

Sig
0.05

Alpha

Treatment
Null
TTL
TTL
E331Q
E331Q
E331Q
Null
Null
Null
Null
TTL
TTL
TTL
TTL
TTL

1
Sig

0.05
0.05
0.05
Etiology
NF
NF
NF
NF
NF
NF
NF
NF
NF
HF
NF
NF
NF
HF
HF

1
0
1
Treatment
E331Q
E331Q
Null
E331Q
Null
TTL
E331Q
Null
TTL
E331Q
E331Q
Null
TTL
E331Q
Null
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Prob

Alpha
0.38027
1
0.09131
8.80E-06
0.05985
7.27E-07
5.63E-12
2.46E-06
2.18E-13
0.27378
0.00692
1
1.04E-03
1
0.00232

0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05

VASH1KD relaxation time (50%) two way ANOVA
Overall ANOVA
DF
Etiology
Treatment
Interaction
Model
Error
Corrected Total

2
1
2
5
462
467

Mean comparison
Etiology
Prob
HFrEF NF
HFpEF NF
HFpEF HFrEF

1.19E-13
2.76E-58
1.15E-22

Treatment
Prob
shVASH scram

6.14E-12

Interaction
etiology
NF
HFrEF
HFrEF
HFrEF
HFrEF
HFrEF
HFpEF
HFpEF
HFpEF
HFpEF
HFpEF
HFpEF
HFpEF
HFpEF
HFpEF

Sum of Squares Mean Square
F Value
P Value
4.75231
2.37616 180.3949
0
0.76623
0.76623
58.171 1.38E-13
0.30826
0.15413 11.70122 1.10E-05
5.6686
1.13372 86.07057
0
6.08545
0.01317 --11.75405 ---Alpha

Sig
0.05
0.05
0.05

Alpha

treatment
shVASH
scram
scram
shVASH
shVASH
shVASH
scram
scram
scram
scram
shVASH
shVASH
shVASH
shVASH
shVASH

1
1
1
Sig

0.05
etiology
NF
NF
NF
NF
NF
HFrEF
NF
NF
HFrEF
HFrEF
NF
NF
HFrEF
HFrEF
HFpEF

1
treatment
scram
scram
shVASH
scram
shVASH
scram
scram
shVASH
scram
shVASH
scram
shVASH
scram
shVASH
scram

98

Prob
1
2.76E-11
2.12E-14
6.89E-02
1.71E-03
3.17E-04
6.14E-48
1.18E-52
1.20E-16
1.26E-33
6.03E-17
1.21E-20
1.00E+00
7.23E-08
2.19E-12

Alpha
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05

TTL/E331Q relaxation time (90%) two way ANOVA
Overall ANOVA
DF
Etiology
Treatment
Interaction
Model
Error
Corrected Total

1
2
2
5
376
381

Mean comparison
Etiology
Prob
HF NF

1.28E-20

Treatment
Null E331Q
TTL E331Q
TTL Null

0.74587
4.31E-04
3.33E-06

Interaction
Etiology
NF
NF
NF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF
HF

Sum of Squares Mean Square
F Value
P Value
3.7062
3.7062
95.7975 2.66E-20
1.0229
0.51145 13.21994 2.83E-06
0.15695
0.07848
2.02848
0.13297
4.90675
0.98135 25.36584 4.71E-22
14.54663
0.03869 --19.45338 ---Alpha

Prob

Sig
0.05

Alpha

Treatment
Null
TTL
TTL
E331Q
E331Q
E331Q
Null
Null
Null
Null
TTL
TTL
TTL
TTL
TTL

1
Sig

0.05
0.05
0.05
Etiology
NF
NF
NF
NF
NF
NF
NF
NF
NF
HF
NF
NF
NF
HF
HF

0
1
1
Treatment
E331Q
E331Q
Null
E331Q
Null
TTL
E331Q
Null
TTL
E331Q
E331Q
Null
TTL
E331Q
Null

Prob
1
0.97709
0.51414
6.26E-08
5.01E-07
8.59E-13
3.69E-11
4.49E-10
1.37E-16
1
0.31838
0.7061
8.20E-04
0.00725
5.30E-05

Alpha
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05

Appendix Table 3. Detailed two-way ANOVA report of human cardiomyocyte contractility
kinetic data shown Chapter 3. Overall ANOVA and mean comparisons including interactions
from two-way ANOVA of contraction time and relaxation time in VASH1KD and TTL/E331Q
overexpression experiments are listed.
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